Adrian Hernandez, PhD
Leadership Education in Adolescent Health (LEAH) Postdoctoral Psychology Fellow, Division of Adolescent and Young Adult Medicine
Clinical Fellow, Harvard Medical School
Image
Adrian Hernandez, PhD
Leadership Education in Adolescent Health (LEAH) Postdoctoral Psychology Fellow, Division of Adolescent and Young Adult Medicine
Clinical Fellow, Harvard Medical School
Medical Services
Languages
English
Education
Undergraduate School
Grand Valley State University
Allendale
MI
Graduate School
Western Michigan University
Kalamazoo
MI
Internship
Clinical and Community Psychology
Yale School of Medicine
New Haven
CT
Professional History
Dr. Adrian J. Hernandez (He/Him/Él) is the Leadership Education in Adolescent Health (LEAH) Postdoctoral Psychology Fellow in the Division of Adolescent and Young Adult Medicine (AYAM) at Boston Children’s Hospital. He also holds an appointment as a Clinical Fellow with Harvard Medical School.
Dr. Hernandez is dedicated to supporting the physical and mental health of youth and their families via direct clinical practice, psychoeducation initiatives, scholarly research, program implementation and improvement, consultation services, and advocacy efforts. In his role at Boston Children’s, Dr. Hernandez primarily provides evidence-based mental health treatment and specialized evaluation services through the Division of AYAM and Outpatient Psychiatry Service, including the Eating Disorders and Strategies for Teen Empowerment and Physical Health (STEP) programs.
He has several areas of clinical interest, such as attention-deficit/hyperactivity disorder (ADHD), affective disorders (i.e., anxiety, depression), borderline personality disorder, education and learning issues, ethnic-racial identity development, justice-involved youth, immigrant and refugee populations, managing stress, and trauma. Dr. Hernandez’s research interests concentrate on understanding the impacts of social determinants of health with a particular focus on drivers of health inequities, such as racism and discrimination.
Publications
Albiglutide and atrial fibrillation in patients with Type 2 diabetes and established cardiovascular disease: insights from the Harmony Outcomes trial. View Abstract
Ethical Considerations for Informed Consent in Acute Myocardial Infarction Clinical Trials. View Abstract
Clinical and financial implications of inpatient and outpatient management of worsening heart failure. View Abstract
Structural abnormalities and effects of sacubitril/valsartan in patients with mildly reduced or preserved ejection fraction and worsening heart failure: The PARAGLIDE-HF trial. View Abstract
Same-Day Discharge After Catheter Ablation of Atrial Fibrillation in the United States. View Abstract
Sodium-glucose co-transporter 2 inhibitors and new-onset diabetes in cardiovascular or kidney disease. View Abstract
Site-Level Variation and Factors Associated With an Outpatient Intravenous Diuretic Strategy for Worsening Heart Failure. View Abstract
Systematic review and meta-analysis of intravenous iron therapy for patients with heart failure and iron deficiency. View Abstract
A Digital Platform to Optimize Guideline-Directed Heart Failure Therapy: Rationale and Design of the AIM-POWER Trial. View Abstract
Severe Heart Failure and Treatment With Dapagliflozin Across the Ejection Fraction Spectrum: DAPA-HF and DELIVER. View Abstract
What Counts for Worsening Heart Failure Events. View Abstract
In-Hospital or Out-of-Hospital Initiation of Sacubitril/Valsartan Versus Valsartan in Patients With Mildly Reduced or Preserved Ejection Fraction After A Worsening Heart Failure Event: The PARAGLIDE-HF Trial. View Abstract
Design of the First in Human Gene Therapy Trial of TLT-101 for Chronic Heart Failure (FIGHT-HF). View Abstract
Embracing Generative Artificial Intelligence in Clinical Research and Beyond: Opportunities, Challenges, and Solutions. View Abstract
EuroQol 5-Dimension Questionnaire in Heart Failure With Reduced, Mildly Reduced, and Preserved Ejection Fraction: A Patient-Level Analysis of DAPA-HF and DELIVER. View Abstract
Prediction and Longer-Term Outcomes of All-cause and Cardiovascular Mortality in the HEART-FID Trial. View Abstract
Ensuring Virtual Vigilance in Decentralized Clinical Trials. View Abstract
Sacubitril/valsartan versus valsartan initiation in patients naïve to renin-angiotensin system inhibitors: Insights from PARAGLIDE-HF. View Abstract
The Fine Art and Science of Translating Trials Results Into Clinical Practice. View Abstract
Empagliflozin in acute myocardial infarction in patients with and without type 2 diabetes: A pre-specified analysis of the EMPACT-MI trial. View Abstract
Resting Heart Rate and Associations With Clinical Measures From the Project Baseline Health Study: Observational Study. View Abstract
Guideline-Directed Medical Therapy After Hospitalization for Acute Heart Failure: Insights From the CONNECT-HF. View Abstract
Lipoprotein (a) Testing in Patients With Atherosclerotic Cardiovascular Disease in 5 Large US Health Systems. View Abstract
Win Ratio Analyses Using a Modified Hierarchical Composite Outcome: Insights From PARAGLIDE-HF. View Abstract
Accelerating evidence generation: Addressing critical challenges and charting a path forward. View Abstract
Real-world exploration of LDL-cholesterol management in patients with atherosclerotic cardiovascular disease. View Abstract
Time to Sustained Recovery Among Outpatients With COVID-19 Receiving Montelukast vs Placebo: The ACTIV-6 Randomized Clinical Trial. View Abstract
In-hospital course of patients with heart failure with improved ejection fraction in the DELIVER trial. View Abstract
Comparing Analytical Methods for Composite End Points in Clinical Trials: Insights from the Vericiguat Global Study in Subjects with Heart Failure With Reduced Ejection Fraction Trial. View Abstract
Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Male and Female Patients: A Secondary Analysis of the ADAPTABLE Randomized Clinical Trial. View Abstract
Optimal Medical Therapy and Outcomes Among Patients With Chronic Heart Failure With Reduced Ejection Fraction. View Abstract
Impact of aspirin dose according to race in secondary prevention of atherosclerotic cardiovascular disease: a secondary analysis of the ADAPTABLE randomised controlled trial. View Abstract
Effects of dapagliflozin according to QRS duration across the spectrum of left ventricular ejection fraction: An analysis of DAPA-HF and DELIVER. View Abstract
Effects of albiglutide on myocardial infarction and ischaemic heart disease outcomes in patients with type 2 diabetes and cardiovascular disease in the Harmony Outcomes trial. View Abstract
Interleukin-6 and Cardiovascular Events in Healthy Adults: MESA. View Abstract
Characterization of peripheral artery disease and associations with traditional risk factors, mobility, and biomarkers in the project baseline health study. View Abstract
Characterization of serum phosphate levels over time with intravenous ferric carboxymaltose versus placebo as treatment for heart failure with reduced ejection fraction and iron deficiency: An exploratory prospective substudy from HEART-FID. View Abstract
Everything, Everywhere All at Once: Evidence Generation and Implementation in the Digital Age. View Abstract
Forecasting the Burden of Cardiovascular Disease and Stroke in the United States Through 2050-Prevalence of Risk Factors and Disease: A Presidential Advisory From the American Heart Association. View Abstract
Association of Sacubitril/Valsartan vs Valsartan With Blood Pressure Changes and Symptomatic Hypotension: the PARAGLIDE-HF Trial. View Abstract
Framework of the strengths and challenges of clinically integrated trials: An expert panel report. View Abstract
Winning or Losing Trials: Making Better Days Matter. View Abstract
Effect of Montelukast vs Placebo on Time to Sustained Recovery in Outpatients with COVID-19: The ACTIV-6 Randomized Clinical Trial. View Abstract
Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis. View Abstract
Effect of dapagliflozin in patients with diabetes and heart failure with mildly reduced or preserved ejection fraction according to background glucose-lowering therapy: A pre-specified analysis of the DELIVER trial. View Abstract
Effects of Sacubitril/Valsartan vs Valsartan in De Novo vs Acute on Chronic HFpEF and HFmrEF. View Abstract
Dapagliflozin and quality of life measured using the EuroQol 5-dimension questionnaire in patients with heart failure with reduced and mildly reduced/preserved ejection fraction. View Abstract
Prognostic Models for Mortality and Morbidity in Heart Failure With Preserved Ejection Fraction. View Abstract
Sex Differences in Heart Failure With Improved Ejection Fraction: The DELIVER Trial. View Abstract
Remote Follow-up in a Heart Failure Pragmatic Trial: Insights From the CONNECT-HF. View Abstract
Empagliflozin after Acute Myocardial Infarction. View Abstract
Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights From the EMPACT-MI Trial. View Abstract
Left Ventricular Function, Congestion, and Effect of Empagliflozin on Heart Failure Risk After Myocardial Infarction. View Abstract
Dapagliflozin and Timing of Prior Heart Failure Hospitalization: A Patient-Level Meta-Analysis of DAPA-HF and DELIVER. View Abstract
Sacubitril/Valsartan in Patients Hospitalized With Decompensated Heart Failure. View Abstract
Dapagliflozin in patients with heart failure and previous myocardial infarction: A participant-level pooled analysis of DAPA-HF and DELIVER. View Abstract
Iron replacement therapy in heart failure: Contextualizing the results of the HEART-FID trial. View Abstract
Dapagliflozin and Mode of Death in Heart Failure With Improved Ejection Fraction: A Post Hoc Analysis of the DELIVER Trial. View Abstract
Cost Effectiveness of Dapagliflozin for Heart Failure Across the Spectrum of Ejection Fraction: An Economic Evaluation Based on Pooled, Individual Participant Data From the DELIVER and DAPA-HF Trials. View Abstract
Recurrent Hospitalizations and Response to Vericiguat in Heart Failure and Reduced Ejection Fraction. View Abstract
Age and Aspirin Dosing in Secondary Prevention of Atherosclerotic Cardiovascular Disease. View Abstract
Effect of albiglutide on cardiovascular outcomes in older adults: A post hoc analysis of a randomized controlled trial. View Abstract
Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial. View Abstract
Hierarchical End Points in Prior Heart Failure Trials and the HEART-FID Trial. View Abstract
Drug development for major chronic health conditions-aligning with growing public health needs: Proceedings from a multistakeholder think tank. View Abstract
Access to Mobile Health Interventions Among Patients Hospitalized With Heart Failure: Insights Into the Digital Divide From the CONNECT-HF mHealth Substudy. View Abstract
Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease and Diabetes Mellitus: A Subgroup Analysis of the ADAPTABLE Trial. View Abstract
Higher-Dose Fluvoxamine and Time to Sustained Recovery in Outpatients With COVID-19: The ACTIV-6 Randomized Clinical Trial. View Abstract
Efficacy of ferric carboxymaltose in heart failure with iron deficiency: an individual patient data meta-analysis. View Abstract
Heart Failure, Investigator-Reported Sleep Apnea and Dapagliflozin: A Patient-Level Pooled Meta-Analysis of DAPA-HF and DELIVER. View Abstract
Lessons From COVID-19 for Pandemic Preparedness: Proceedings From a Multistakeholder Think Tank. View Abstract
Effects of Dapagliflozin in Patients in Asia: A Post Hoc Subgroup Analysis From the DELIVER Trial. View Abstract
The Future of Clinical Trials: Artificial to Augmented to Applied Intelligence. View Abstract
Author Correction: Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial. View Abstract
Proactive Algorithm Monitoring to Ensure Health Equity. View Abstract
Ferric Carboxymaltose in Heart Failure with Iron Deficiency. Reply. View Abstract
Effectiveness and Safety of Enteric-Coated vs Uncoated Aspirin in Patients With Cardiovascular Disease: A Secondary Analysis of the ADAPTABLE Randomized Clinical Trial. View Abstract
Efficacy of Dapagliflozin According to Heart Rate: A Patient-Level Pooled Analysis of DAPA-HF and DELIVER. View Abstract
Use of Win Statistics to Analyze Outcomes in the DAPA-HF and DELIVER Trials. View Abstract
Dapagliflozin and Apparent Treatment-Resistant Hypertension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The DELIVER Trial. View Abstract
Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Patients Treated With P2Y12 Inhibitors. View Abstract
Impact of COVID-19 in patients with heart failure with mildly reduced or preserved ejection fraction enrolled in the DELIVER trial. View Abstract
Contemporary Use and Implications of Beta-Blockers in Patients With HFmrEF or HFpEF: The DELIVER Trial. View Abstract
Inhaled Fluticasone Furoate for Outpatient Treatment of Covid-19. View Abstract
Mitochondrial metabolites predict adverse cardiovascular events in individuals with diabetes. View Abstract
Cost-Effectiveness of Vericiguat in Patients With Heart Failure With Reduced Ejection Fraction: The VICTORIA Randomized Clinical Trial. View Abstract
Influence of background medical therapy on efficacy and safety of dapagliflozin in patients with heart failure with improved ejection fraction in the DELIVER trial. View Abstract
Outpatient Worsening Among Patients With Mildly Reduced and Preserved Ejection Fraction Heart Failure in the DELIVER Trial. View Abstract
Ferric Carboxymaltose in Heart Failure with Iron Deficiency. View Abstract
Baseline characteristics of patients enrolled in the EMPACT-MI trial. View Abstract
Dapagliflozin in Patients With Heart Failure and Deterioration in Renal Function. View Abstract
Efficacy of Dapagliflozin According to Geographic Location of Patients With Heart Failure. View Abstract
Baseline characteristics of patients in the randomized study to investigate the efficacy and safety of ferric carboxymaltose as treatment for heart failure with iron deficiency: HEART-FID trial. View Abstract
Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF. View Abstract
Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial. View Abstract
GLP-1 Receptor Agonist Therapy With and Without SGLT2 Inhibitors in Patients With Type 2 Diabetes. View Abstract
Common Variants on FGD5 Increase Hazard of Mortality or Rehospitalization in Patients With Heart Failure From the ASCEND-HF Trial. View Abstract
Morbidity and Mortality Associated With Heart Failure in Acute Coronary Syndrome: A Pooled Analysis of 4 Clinical Trials. View Abstract
"Click and mortar" opportunities for digitization and consumerism in trials. View Abstract
Splanchnic Nerve Modulation Effects on Surrogate Measures of Venous Capacitance. View Abstract
Background Medical Therapy and Clinical Outcomes From the VICTORIA Trial. View Abstract
Association of Dapagliflozin vs Placebo With Individual Kansas City Cardiomyopathy Questionnaire Components in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the DELIVER Trial. View Abstract
2022 ACC/AHA guideline for the diagnosis and management of aortic disease: A report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. View Abstract
Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVER. View Abstract
Internet Versus Noninternet Participation in a Decentralized Clinical Trial: Lessons From the ADAPTABLE Study. View Abstract
Recent Vitamin K Antagonist Use and Intracranial Hemorrhage After Endovascular Thrombectomy for Acute Ischemic Stroke. View Abstract
Classification of Heart Failure Events by Severity: Insights From the VICTORIA Trial. View Abstract
Safety and efficacy of hydroxychloroquine as prophylactic against COVID-19 in healthcare workers: a meta-analysis of randomised clinical trials. View Abstract
Opportunities and Achievement of Medication Initiation Among Inpatients With Heart Failure With Reduced Ejection Fraction. View Abstract
Effects of dapagliflozin on heart failure hospitalizations according to severity of inpatient course: Insights from DELIVER and DAPA-HF. View Abstract
Renal and blood pressure effects of dapagliflozin in recently hospitalized patients with heart failure with mildly reduced or preserved ejection fraction: Insights from the DELIVER trial. View Abstract
Effect of dapagliflozin on health status and quality of life across the spectrum of ejection fraction: Participant-level pooled analysis from the DAPA-HF and DELIVER trials. View Abstract
Comparison of the effectiveness and safety of 2 aspirin doses in secondary prevention of cardiovascular outcomes in patients with chronic kidney disease: A subgroup analysis of ADAPTABLE. View Abstract
Effect of Dapagliflozin on Total Heart Failure Events in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the DELIVER Trial. View Abstract
Cardio-Renal-Metabolic Overlap, Outcomes, and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction. View Abstract
Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Polypharmacy Status. View Abstract
Angiotensin-Neprilysin Inhibition in Patients With Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure. View Abstract
Operational challenges and mitigation measures during the COVID-19 pandemic-Lessons from DELIVER. View Abstract
Proteomic Pathways across Ejection Fraction Spectrum in Heart Failure: an EXSCEL Substudy. View Abstract
Pragmatic evaluation of events and benefits of lipid lowering in older adults (PREVENTABLE): Trial design and rationale. View Abstract
Ejection Fraction, Biomarkers, and Outcomes and Impact of Vericiguat on Outcomes Across EF in VICTORIA. View Abstract
Association of Dapagliflozin Use With Clinical Outcomes and the Introduction of Uric Acid-Lowering Therapy and Colchicine in Patients With Heart Failure With and Without Gout: A Patient-Level Pooled Meta-analysis of DAPA-HF and DELIVER. View Abstract
Outcomes among patients with peripheral artery disease in the Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-Term Effectiveness (ADAPTABLE) study. View Abstract
Splanchnic nerve block with botulinum toxin for therapy of chronic heart failure - mechanism of action (SPONGE-HF). View Abstract
Effect of Higher-Dose Ivermectin for 6 Days vs Placebo on Time to Sustained Recovery in Outpatients With COVID-19: A Randomized Clinical Trial. View Abstract
Patient Characteristics, Outcomes, and Effects of Dapagliflozin According to the Duration of Heart Failure: A Prespecified Analysis of the DELIVER Trial. View Abstract
Clinical Implications of Negatively Adjudicated Heart Failure Events: Data From the VICTORIA Study. View Abstract
Rationale, Design and Baseline Characteristics of the PARAGLIDE-HF Trial: Sacubitril/Valsartan vs Valsartan in HFmrEF and HFpEF With a Worsening Heart Failure Event. View Abstract
Dapagliflozin in Black and White Patients With Heart Failure Across the Ejection Fraction Spectrum. View Abstract
Effect of Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial. View Abstract
Hydroxychloroquine for pre-exposure prophylaxis of COVID-19 in health care workers: a randomized, multicenter, placebo-controlled trial Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine (HERO-HCQ). View Abstract
Omecamtiv Mecarbil: Decisional Dilemmas and Regulatory Science - Opportunities for Improvement? View Abstract
Assessment of Biomarkers of Myocardial injury, Inflammation, and Renal Function in Heart Failure With Reduced Ejection Fraction: The VICTORIA Biomarker Substudy. View Abstract
Dapagliflozin and Kidney Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the DELIVER Randomized Clinical Trial. View Abstract
External validation of the ADA score for predicting thrombosis among acutely ill hospitalized medical patients from the APEX Trial. View Abstract
Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial. View Abstract
Effect of Ivermectin 600 µg/kg for 6 days vs Placebo on Time to Sustained Recovery in Outpatients with Mild to Moderate COVID-19: A Randomized Clinical Trial. View Abstract
Effect of Dapagliflozin on Health Status in Patients With Preserved or Mildly Reduced Ejection Fraction. View Abstract
Assessing Heuristic Bias During Care for Patients Hospitalized for Heart Failure: Get With The Guidelines-Heart Failure. View Abstract
Time to Clinical Benefit of Dapagliflozin in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial. View Abstract
Concordance Between Patient-Reported Health Data and Electronic Health Data in the ADAPTABLE Trial. View Abstract
Utilization and Outcomes of Extracorporeal Membrane Oxygenation Following Traumatic Brain Injury in the United States. View Abstract
Protein biomarkers of cardiac remodeling and inflammation associated with HFpEF and incident events. View Abstract
Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double-blind, randomised, placebo-controlled trial. View Abstract
Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartan. View Abstract
Sex Differences in Characteristics, Outcomes, and Treatment Response With Dapagliflozin Across the Range of Ejection Fraction in Patients With Heart Failure: Insights From DAPA-HF and DELIVER. View Abstract
Association of post-vaccination adverse reactions after influenza vaccine with mortality and cardiopulmonary outcomes in patients with high-risk cardiovascular disease: the INVESTED trial. View Abstract
Dapagliflozin for heart failure according to body mass index: the DELIVER trial. View Abstract
Fluvoxamine for Outpatient Treatment of COVID-19: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial. View Abstract
Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial. View Abstract
Evaluating the Application of Chronic Heart Failure Therapies and Developing Treatments in Individuals With Recent Myocardial Infarction: A Review. View Abstract
Assessing the Impact of the American Heart Association's Research Portfolio: A Scientific Statement From the American Heart Association. View Abstract
A multicenter program for electronic health record screening for patients with heart failure with preserved ejection fraction: Lessons from the DELIVER-EHR initiative. View Abstract
Heart Failure Strategically Focused Research Network: Summary of Results and Future Directions. View Abstract
Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial. View Abstract
Efficacy and Safety of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Age: The DELIVER Trial. View Abstract
Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER. View Abstract
SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. View Abstract
Atrial Fibrillation and Dapagliflozin Efficacy in Patients With Preserved or Mildly Reduced Ejection Fraction. View Abstract
Estimated Long-Term Benefit of Dapagliflozin in Patients With Heart Failure. View Abstract
Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection Fraction. View Abstract
Influence of NT-proBNP on Efficacy of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction. View Abstract
Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial. View Abstract
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. View Abstract
General Anxiety Disorder-7 Questionnaire as a marker of low socioeconomic status and inequity. View Abstract
The Association of Digital Health Application Use With Heart Failure Care and Outcomes: Insights From CONNECT-HF. View Abstract
Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan: insights from the VICTORIA trial. View Abstract
Outcomes After Acute Coronary Syndrome in Patients With Diabetes Mellitus and Peripheral Artery Disease (from the TRACER, TRILOGY-ACS, APPRAISE-2, and PLATO Clinical Trials). View Abstract
Sequential Evaluation of NT-proBNP in Heart Failure: Insights Into Clinical Outcomes and Efficacy of Vericiguat. View Abstract
Landscape of coronavirus disease 2019 clinical trials: New frontiers and challenges. View Abstract
Tolerability of Sacubitril/Valsartan in Patients With Advanced Heart Failure: Analysis of the LIFE Trial Run-In. View Abstract
Angiotensin Receptor Neprilysin Inhibition and Associated Outcomes by Race and Ethnicity in Patients With Heart Failure With Reduced Ejection Fraction: Data From CHAMP-HF. View Abstract
Preface to theme issue on pragmatic and virtual trials: Progress and challenges. View Abstract
Patient-reported and Clinical Outcomes Among Patients Hospitalized for Heart Failure With Reduced Versus Preserved Ejection Fraction. View Abstract
Vericiguat and Health-Related Quality of Life in Patients With Heart Failure With Reduced Ejection Fraction: Insights From the VICTORIA Trial. View Abstract
Plasma metabolites associated with functional and clinical outcomes in heart failure with reduced ejection fraction with and without type 2 diabetes. View Abstract
Could Neprilysin Be Already Inhibited by BNP in the LIFE Trial?-Reply. View Abstract
Sodium Glucose Cotransporter-2 Inhibition for Acute Myocardial Infarction: JACC Review Topic of the Week. View Abstract
The impact of COVID-19 on pragmatic clinical trials: lessons learned from the NIH Health Care Systems Research Collaboratory. View Abstract
Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial. View Abstract
Iterative approaches to the use of electronic health records data for large pragmatic studies. View Abstract
Acute Decompensated Heart Failure in the Setting of Acute Coronary Syndrome. View Abstract
Quantitative Blood Volume Analysis and Hemodynamic Measures of Vascular Compliance in Patients With Worsening Heart Failure. View Abstract
Health System-Level Performance in Prescribing Guideline-Directed Medical Therapy for Patients With Heart Failure With Reduced Ejection Fraction: Results From the CONNECT-HF Trial. View Abstract
Multiple cArdiac seNsors for mAnaGEment of Heart Failure (MANAGE-HF) - Phase I Evaluation of the Integration and Safety of the HeartLogic Multisensor Algorithm in Patients With Heart Failure. View Abstract
Patient partnership in cardiovascular clinical trials. View Abstract
2022 American College of Cardiology/American Heart Association/Heart Failure Society of America Guideline for the Management of Heart Failure: Executive Summary. View Abstract
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. View Abstract
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. View Abstract
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. View Abstract
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. View Abstract
The association of improvement in left ventricular ejection fraction with outcomes in patients with heart failure with reduced ejection fraction: data from CHAMP-HF. View Abstract
Vericiguat in patients with coronary artery disease and heart failure with reduced ejection fraction. View Abstract
The challenges of data safety monitoring for a pragmatic study: Lessons from the ADAPTABLE study. View Abstract
Medical Therapy During Hospitalization for Heart Failure With Reduced Ejection Fraction: The VICTORIA Registry. View Abstract
Racial/Ethnic Disparities in Healthcare Worker Experiences During the COVID-19 Pandemic: An Analysis of the HERO Registry. View Abstract
Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial. View Abstract
Early Vasopressor Utilization Strategies and Outcomes in Critically Ill Patients With Severe Traumatic Brain Injury. View Abstract
Association of Recent Use of Non-Vitamin K Antagonist Oral Anticoagulants With Intracranial Hemorrhage Among Patients With Acute Ischemic Stroke Treated With Alteplase. View Abstract
Inverse relationship between body mass index and risk of venous thromboembolism among medically ill hospitalized patients: Observations from the APEX trial. View Abstract
Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. View Abstract
Identifying Treatments for Stage C2 Heart Failure. View Abstract
Validation of Cardiovascular End Points Ascertainment Leveraging Multisource Electronic Health Records Harmonized Into a Common Data Model in the ADAPTABLE Randomized Clinical Trial. View Abstract
Clinical Outcomes With Metformin and Sulfonylurea Therapies Among Patients With Heart Failure and Diabetes. View Abstract
Achieving More Rapid Door-to-Needle Times and Improved Outcomes in Acute Ischemic Stroke in a Nationwide Quality Improvement Intervention. View Abstract
Relationship of Nonalcoholic Fatty Liver Disease and Heart Failure With Preserved Ejection Fraction. View Abstract
Lifetime cost-effectiveness simulation of once-weekly exenatide in type 2 diabetes: A cost-utility analysis based on the EXSCEL trial. View Abstract
Dysglycemia and incident heart failure among blacks: The jackson heart study. View Abstract
Identifying patients at increased risk for poor outcomes from heart failure with reduced ejection fraction: the PROMPT-HF risk model. View Abstract
A Hospital and Postdischarge Quality Improvement Intervention and Outcomes and Care for Patients With Heart Failure With Reduced Ejection Fraction-Reply. View Abstract
Comparative Effectiveness of Dosing of Medical Therapy for Heart Failure: From the CHAMP-HF Registry. View Abstract
Blood Pressure and Safety Events With Vericiguat in the VICTORIA Trial. View Abstract
Impact of the COVID-19 Pandemic on Cardiovascular Science: Anticipating Problems and Potential Solutions: A Presidential Advisory From the American Heart Association. View Abstract
Polyvascular disease and increased risk of cardiovascular events in patients with type 2 diabetes: Insights from the EXSCEL trial. View Abstract
Diuretic Changes, Health Care Resource Utilization, and Clinical Outcomes for Heart Failure With Reduced Ejection Fraction: From the Change the Management of Patients With Heart Failure Registry. View Abstract
Hemoglobin and Clinical Outcomes in the Vericiguat Global Study in Patients With Heart Failure and Reduced Ejection Fraction (VICTORIA). View Abstract
Treatment Persistence of Renin-Angiotensin-Aldosterone-System Inhibitors Over Time in Heart Failure with Reduced Ejection Fraction. View Abstract
Participation in a Heart Failure Clinical Trial: Perspectives and Opportunities From the VICTORIA Trial and VICTORIA Simultaneous Registry. View Abstract
Aspirin Dosing in Cardiovascular Disease. Reply. View Abstract
Design of the Healthcare Worker Exposure Response and Outcomes (HERO) research platform. View Abstract
Transmethylamine-N-Oxide Is Associated With Diffuse Cardiac Fibrosis in People Living With HIV. View Abstract
Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. View Abstract
Effect of a Hospital and Postdischarge Quality Improvement Intervention on Clinical Outcomes and Quality of Care for Patients With Heart Failure With Reduced Ejection Fraction: The CONNECT-HF Randomized Clinical Trial. View Abstract
The use of electronic health records for recruitment in clinical trials: a mixed methods analysis of the Harmony Outcomes Electronic Health Record Ancillary Study. View Abstract
Vericiguat in patients with atrial fibrillation and heart failure with reduced ejection fraction: insights from the VICTORIA trial. View Abstract
Assessment of North American Clinical Research Site Performance During the Start-up of Large Cardiovascular Clinical Trials. View Abstract
Multiparameter diagnostic sensor measurements in heart failure patients presenting with SARS-CoV-2 infection. View Abstract
Is Learning Worth the Trouble? - Improving Health Care System Participation in Embedded Research. View Abstract
Clinical Outcome Predictions for the VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA) Trial. View Abstract
Enabling patient-reported outcome measures in clinical trials, exemplified by cardiovascular trials. View Abstract
Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial. View Abstract
Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA (Vericiguat Global Study in Subjects with HFrEF) trial. View Abstract
Growth differentiation factor-15, treatment with liraglutide, and clinical outcomes among patients with heart failure. View Abstract
Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event: Insights From the VICTORIA Trial. View Abstract
Early diuretic strategies and the association with In-hospital and Post-discharge outcomes in acute heart failure. View Abstract
Randomized Placebo-Controlled Trial of Ferric Carboxymaltose in Heart Failure With Iron Deficiency: Rationale and Design. View Abstract
Impact of Percutaneous Coronary Intervention on Outcomes in Patients With Heart Failure: JACC State-of-the-Art Review. View Abstract
Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease. View Abstract
2020 American Heart Association and American College of Cardiology Consensus Conference on Professionalism and Ethics: A Consensus Conference Report. View Abstract
2020 American Heart Association and American College of Cardiology Consensus Conference on Professionalism and Ethics: A Consensus Conference Report. View Abstract
Splanchnic nerve modulation in heart failure: mechanistic overview, initial clinical experience, and safety considerations. View Abstract
2020 ACC/AHA guideline for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. View Abstract
Comparison of New York Heart Association Class and Patient-Reported Outcomes for Heart Failure With Reduced Ejection Fraction. View Abstract
Association between sacubitril/valsartan initiation and real-world health status trajectories over 18 months in heart failure with reduced ejection fraction. View Abstract
2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. View Abstract
Effect of once-weekly exenatide on hospitalization for acute coronary syndrome or coronary revascularization in patients with type 2 diabetes mellitus. View Abstract
Prognostic Role of Prior Heart Failure Hospitalization Among Patients Hospitalized for Worsening Chronic Heart Failure. View Abstract
Predicting major adverse limb events in individuals with type 2 diabetes: Insights from the EXSCEL trial. View Abstract
Sex Differences in Clinical Course and Patient-Reported Outcomes Among Patients Hospitalized for Heart Failure. View Abstract
Splanchnic Nerve Block Mediated Changes in Stressed Blood Volume in Heart Failure. View Abstract
Impact of the Early Phase of the COVID-19 Pandemic on US Healthcare Workers: Results from the HERO Registry. View Abstract
Corrigendum to "Impact of baseline covariate imbalance on bias in treatment effect estimation in cluster randomized trials: Race as an example" [Contemporary Clinical Trials volume 88 (2020) 105775]. View Abstract
Cardiovascular and renal safety of metformin in patients with diabetes and moderate or severe chronic kidney disease: Observations from the EXSCEL and SAVOR-TIMI 53 cardiovascular outcomes trials. View Abstract
Patterns of antidepressant therapy and clinical outcomes among ischaemic stroke survivors. View Abstract
Streamlining the institutional review board process in pragmatic randomized clinical trials: challenges and lessons learned from the Aspirin Dosing: A Patient-centric Trial Assessing Benefits and Long-Term Effectiveness (ADAPTABLE) trial. View Abstract
Interleukin-6 and Outcomes in Acute Heart Failure: An ASCEND-HF Substudy. View Abstract
Variation in use and dosing escalation of renin angiotensin system, mineralocorticoid receptor antagonist, angiotensin receptor neprilysin inhibitor and beta-blocker therapies in heart failure and reduced ejection fraction: Association of comorbidities. View Abstract
Generating evidence for therapeutic effects: the need for well-conducted randomized trials. View Abstract
Effect of High-Dose Trivalent vs Standard-Dose Quadrivalent Influenza Vaccine on Mortality or Cardiopulmonary Hospitalization in Patients With High-risk Cardiovascular Disease: A Randomized Clinical Trial. View Abstract
Implications of peripheral oedema in heart failure with preserved ejection fraction: a heart failure network analysis. View Abstract
Heart Failure Hospitalization and Guideline-Directed Prescribing Patterns Among Heart Failure With Reduced Ejection Fraction Patients. View Abstract
Ultrafiltration in Acute Heart Failure: Implications of Ejection Fraction and Early Response to Treatment From CARRESS-HF. View Abstract
The Use of Sacubitril/Valsartan for Hospitalized Heart Failure-Why Do We Care About Cost and Value? View Abstract
Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The VITALITY-HFpEF Randomized Clinical Trial. View Abstract
Plasma Volume Status and Its Association With In-Hospital and Postdischarge Outcomes in Decompensated Heart Failure. View Abstract
N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes: Vericiguat Heart Failure With Reduced Ejection Fraction Study. View Abstract
PCORnet® 2020: current state, accomplishments, and future directions. View Abstract
PROVIDE-HF primary results: Patient-Reported Outcomes inVestigation following Initiation of Drug therapy with Entresto (sacubitril/valsartan) in heart failure. View Abstract
Disseminating trial results: We can have both faster and better. View Abstract
Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure: The Need for Further Evidence Generation and Practice Guidelines Optimization. View Abstract
Improving Care for Patients after Hospitalization with AKI. View Abstract
Hydroxychloroquine, Coronavirus Disease 2019, and QT Prolongation. View Abstract
National Hospital Quality Rankings: Improving the Value of Information in Hospital Rating Systems. View Abstract
Sample size requirements for detecting treatment effect heterogeneity in cluster randomized trials. View Abstract
Expected vs Actual Outcomes of Elective Initiation of Inotropic Therapy During Heart Failure Hospitalization. View Abstract
Weighing the Benefits and Risks of Proliferating Observational Treatment Assessments: Observational Cacophony, Randomized Harmony. View Abstract
Randomized Trials Versus Common Sense and Clinical Observation: JACC Review Topic of the Week. View Abstract
Heart Failure Clinical Trial Operations During the COVID-19 Pandemic: Results From a Multicenter Survey. View Abstract
Improving Cardiovascular Drug and Device Development and Evidence Through Patient-Centered Research and Clinical Trials: A Call to Action From the Value in Healthcare Initiative's Partnering With Regulators Learning Collaborative. View Abstract
Improvement in Left Ventricular Ejection Fraction in Outpatients With Heart Failure With Reduced Ejection Fraction: Data From CHAMP-HF. View Abstract
Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial. View Abstract
Splanchnic Nerve Block for Chronic Heart Failure. View Abstract
Designing, Conducting, Monitoring, and Analyzing Data from Pragmatic Randomized Clinical Trials: Proceedings from a Multi-stakeholder Think Tank Meeting. View Abstract
Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). View Abstract
Periprocedural Risk and Survival Associated With Implantable Cardioverter-Defibrillator Placement in Older Patients With Advanced Heart Failure. View Abstract
Outcomes and cost among Medicare beneficiaries hospitalized for heart failure assigned to accountable care organizations. View Abstract
Contemporary Treatment Patterns and Clinical Outcomes of Comorbid Diabetes Mellitus and HFrEF: The CHAMP-HF Registry. View Abstract
Effects of Liraglutide on Worsening Renal Function Among Patients With Heart Failure With Reduced Ejection Fraction: Insights From the FIGHT Trial. View Abstract
Rationale and Design of the Aspirin Dosing-A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE) Trial. View Abstract
Evidence from Pragmatic Trials during Routine Care - Slouching toward a Learning Health System. View Abstract
Lipoprotein (a): An Update on a Marker of Residual Risk and Associated Clinical Manifestations. View Abstract
Representativeness of the PIONEER-HF Clinical Trial Population in Patients Hospitalized With Heart Failure and Reduced Ejection Fraction. View Abstract
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. View Abstract
The burden of non-cardiac comorbidities and association with clinical outcomes in an acute heart failure trial - insights from ASCEND-HF. View Abstract
Testing for Coronary Artery Disease in Older Patients With New-Onset Heart Failure: Findings From Get With The Guidelines-Heart Failure. View Abstract
Time for NIH to lead on data sharing. View Abstract
Trends in Treatment for Patients Hospitalized with Heart Failure with Preserved Ejection Fraction Before and After Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT). View Abstract
The Status of Specialized Ambulatory Heart Failure Care in Canada: A Joint Canadian Heart Failure Society and Canadian Cardiovascular Society Heart Failure Guidelines Survey. View Abstract
PredischaRge initiation of Ivabradine in the ManagEment of Heart Failure: Results of the PRIME-HF Trial. View Abstract
Exploring the Possible Impact of Unbalanced Open-Label Drop-In of Glucose-Lowering Medications on EXSCEL Outcomes. View Abstract
Association between potassium level and outcomes in heart failure with reduced ejection fraction: a cohort study from the Swedish Heart Failure Registry. View Abstract
Association of Implantable Device Measured Physical Activity With Hospitalization for Heart Failure. View Abstract
Prediction and validation of exenatide risk marker effects on progression of renal disease: Insights from EXSCEL. View Abstract
Does Guideline-Directed Medical Therapy for Heart Failure Offer Benefits After LVAD Placement?-A Call for a Randomized Clinical Trial. View Abstract
CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis. View Abstract
Machine learning to predict venous thrombosis in acutely ill medical patients. View Abstract
A Novel In-hospital Congestion Score to Risk Stratify Patients Admitted for Worsening Heart Failure (from ASCEND-HF). View Abstract
Renal Dysfunction in Heart Failure With Preserved Ejection Fraction: Insights From the RELAX Trial. View Abstract
Safety and Outcomes of Intravenous tPA in Acute Ischemic Stroke Patients With Prior Stroke Within 3 Months: Findings From Get With The Guidelines-Stroke. View Abstract
Considerations for using distributed research networks to conduct aspects of randomized trials. View Abstract
Strict Versus Lenient Versus Poor Rate Control Among Patients With Atrial Fibrillation and Heart Failure (from the Get With The Guidelines - Heart Failure Program). View Abstract
Confirming the Bidirectional Nature of the Association Between Severe Hypoglycemic and Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL. View Abstract
Biomarker Profile of Left Atrial Myopathy in Heart Failure With Preserved Ejection Fraction: Insights From the RELAX Trial. View Abstract
Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Critical Evaluation of Clinical and Regulatory Issues. View Abstract
From Theory to Practice: The Use of Real-World Data to Evaluate New Heart Failure Therapies. View Abstract
Rhythm Control Versus Rate Control in Patients With Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction: Insights From Get With The Guidelines-Heart Failure. View Abstract
Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial. View Abstract
Incidence of statin use in older adults with and without cardiovascular disease and diabetes mellitus, January 2008- March 2018. View Abstract
Within-Trial Evaluation of Medical Resources, Costs, and Quality of Life Among Patients With Type 2 Diabetes Participating in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). View Abstract
Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: Results From the EXSCEL Trial. View Abstract
Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial. View Abstract
Eligibility of sodium-glucose co-transporter-2 inhibitors among patients with diabetes mellitus admitted for heart failure. View Abstract
Are existing and emerging biomarkers associated with cardiorespiratory fitness in patients with chronic heart failure? View Abstract
Diastolic Dysfunction in Patients With Human Immunodeficiency Virus Receiving Antiretroviral Therapy: Results From the CHART Study. View Abstract
The Future of Wearables in Heart Failure Patients. View Abstract
Care Optimization Through Patient and Hospital Engagement Clinical Trial for Heart Failure: Rationale and design of CONNECT-HF. View Abstract
Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial. View Abstract
PARAGON-HF Clinical Trial Eligibility in a Population of Patients Hospitalized With Heart Failure. View Abstract
The Hospital Readmissions Reduction Program: Nationwide Perspectives and Recommendations: A JACC: Heart Failure Position Paper. View Abstract
Representativeness of a Heart Failure Trial by Race and Sex: Results From ASCEND-HF and GWTG-HF. View Abstract
Clinical Effectiveness of Direct Oral Anticoagulants vs Warfarin in Older Patients With Atrial Fibrillation and Ischemic Stroke: Findings From the Patient-Centered Research Into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) Study. View Abstract
Comparison of Hydralazine/Nitrate and Angiotensin Receptor Neprilysin Inhibitor Use Among Black Versus Nonblack Americans With Heart Failure and Reduced Ejection Fraction (from CHAMP-HF). View Abstract
Revisiting the Role of Aspirin for the Primary Prevention of Cardiovascular Disease. View Abstract
Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failure-Related Outcomes: Insights From the EXSCEL Trial. View Abstract
Safety and efficacy of the partial adenosine A1 receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced ejection fraction: a phase IIb, randomized, double-blind, placebo-controlled trial. View Abstract
Thrombolytic therapy in older acute ischemic stroke patients with gastrointestinal malignancy or recent bleeding. View Abstract
Haemoconcentration during treatment of acute heart failure with cardiorenal syndrome: from the CARRESS-HF trial. View Abstract
Intravenous Tissue Plasminogen Activator in Stroke Mimics. View Abstract
Assessing heterogeneity of treatment effect analyses in health-related cluster randomized trials: A systematic review. View Abstract
Circulating Neprilysin in Patients With Heart Failure and Preserved Ejection Fraction. View Abstract
Recent Myocardial Infarction is Associated With Increased Risk in Older Adults With Acute Ischemic Stroke Receiving Thrombolytic Therapy. View Abstract
Evolving the Hospital Readmissions Reduction Program: A Call for Peace, Happiness, and Improved Patient-Centered Outcomes. View Abstract
Impact of baseline covariate imbalance on bias in treatment effect estimation in cluster randomized trials: Race as an example. View Abstract
The Burden of Congestion in Patients Hospitalized With Acute Decompensated Heart Failure. View Abstract
Addressing guideline and policy changes during pragmatic clinical trials. View Abstract
PCSK9 Inhibitor Use in the Real World: Data From the National Patient-Centered Research Network. View Abstract
Rationale and Design of the VITALITY-HFpEF Trial. View Abstract
Trends in Readmissions and Length of Stay for Patients Hospitalized With Heart Failure in Canada and the United States. View Abstract
Intravenous Tissue-Type Plasminogen Activator in Acute Ischemic Stroke Patients With History of Stroke Plus Diabetes Mellitus. View Abstract
Changes in Serum Calcitonin Concentrations, Incidence of Medullary Thyroid Carcinoma, and Impact of Routine Calcitonin Concentration Monitoring in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL). View Abstract
Characterization of Major and Clinically Relevant Non-Major Bleeds in the APEX Trial. View Abstract
Prognostic Implications of Changes in Amino-Terminal Pro-B-Type Natriuretic Peptide in Acute Decompensated Heart Failure: Insights From ASCEND-HF. View Abstract
Identifying responders to oral iron supplementation in heart failure with a reduced ejection fraction: a post-hoc analysis of the IRONOUT-HF trial. View Abstract
Transitioning to the National Institutes of Health single institutional review board model: Piloting the use of the Streamlined, Multi-site, Accelerated Resources for Trials IRB Reliance. View Abstract
Heart failure drug treatment. View Abstract
Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction. View Abstract
What Is Needed Now to Improve Cardiovascular Clinical Registries in the Future. View Abstract
Reduction of Cardiovascular Mortality and Ischemic Events in Acute Medically Ill Patients. View Abstract
Extended-duration betrixaban versus shorter-duration enoxaparin for venous thromboembolism prophylaxis in critically ill medical patients: an APEX trial substudy. View Abstract
Heart Failure With Preserved Ejection Fraction and Diabetes: JACC State-of-the-Art Review. View Abstract
Spironolactone in Acute Heart Failure Patients With Renal Dysfunction and Risk Factors for Diuretic Resistance: From the ATHENA-HF Trial. View Abstract
Target Doses of Heart Failure Medical Therapy and Blood Pressure: Insights From the CHAMP-HF Registry. View Abstract
Relationship Between Hospital Characteristics and Early Adoption of Angiotensin-Receptor/Neprilysin Inhibitor Among Eligible Patients Hospitalized for Heart Failure. View Abstract
Hospital-based quality improvement interventions for patients with heart failure: a systematic review. View Abstract
Long-term outcomes for heart failure patients with and without diabetes: From the Get With The Guidelines-Heart Failure Registry. View Abstract
High-Density Lipoprotein Particle Subfractions in Heart Failure With Preserved or Reduced Ejection Fraction. View Abstract
Reply: Vaccination in Patients With Heart Failure: An Established Recommendation in Patients With Chronic Heart Disease. View Abstract
Characteristics of Acute Heart Failure Hospitalizations Based on Presenting Severity. View Abstract
Statistical Code for Clinical Research Papers. View Abstract
Estimation of Acutely Ill Medical Patients at Venous Thromboembolism Risk Eligible for Extended Thromboprophylaxis Using APEX Criteria in US Hospitals. View Abstract
Providing Individual Research Results to Participants-Reply. View Abstract
Splanchnic nerve block for decompensated chronic heart failure: splanchnic-HF. View Abstract
High-Sensitivity Troponin I in Hospitalized and Ambulatory Patients With Heart Failure With Preserved Ejection Fraction: Insights From the Heart Failure Clinical Research Network. View Abstract
Is Time From Last Hospitalization for Heart Failure to Placement of a Primary Prevention Implantable Cardioverter-Defibrillator Associated With Patient Outcomes? View Abstract
Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL. View Abstract
Glycated Hemoglobin and Outcomes of Heart Failure (from Get With the Guidelines-Heart Failure). View Abstract
Association of Kidney Function With 30-Day and 1-Year Poststroke Mortality and Hospital Readmission. View Abstract
Engaging patients throughout the health system: A landscape analysis of cold-call policies and recommendations for future policy change. View Abstract
Effects of Once-Weekly Exenatide on Clinical Outcomes in Patients With Preexisting Cardiovascular Disease. View Abstract
Asymptomatic Deep Vein Thrombosis is Associated with an Increased Risk of Death: Insights from the APEX Trial. View Abstract
Effect of Inorganic Nitrite vs Placebo on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction: The INDIE-HFpEF Randomized Clinical Trial. View Abstract
History of Atrial Fibrillation and Trajectory of Decongestion in Acute Heart Failure. View Abstract
Inverse relationship of serum albumin to the risk of venous thromboembolism among acutely ill hospitalized patients: Analysis from the APEX trial. View Abstract
International Comparison of Patient Characteristics and Quality of Care for Ischemic Stroke: Analysis of the China National Stroke Registry and the American Heart Association Get With The Guidelines--Stroke Program. View Abstract
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. View Abstract
Effect of Once-Weekly Exenatide on Clinical Outcomes According to Baseline Risk in Patients With Type 2 Diabetes Mellitus: Insights From the EXSCEL Trial. View Abstract
Trends in Hospice Discharge and Relative Outcomes Among Medicare Patients in the Get With The Guidelines-Heart Failure Registry. View Abstract
Relationship Between Enrolling Country Income Level and Patient Profile, Protocol Completion, and Trial End Points. View Abstract
The emerging role of novel antihyperglycemic agents in the treatment of heart failure and diabetes: A focus on cardiorenal outcomes. View Abstract
Rationale and design of the phase 2b clinical trials to study the effects of the partial adenosine A1-receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced (PANTHEON) and preserved (PANACHE) ejection fraction. View Abstract
Intravenous tPA (Tissue-Type Plasminogen Activator) in Patients With Acute Ischemic Stroke Taking Non-Vitamin K Antagonist Oral Anticoagulants Preceding Stroke. View Abstract
Patient, Provider, and Practice Characteristics Associated With Sacubitril/Valsartan Use in the United States. View Abstract
Splanchnic Nerve Block for Acute Heart Failure. View Abstract
Liraglutide and weight loss among patients with advanced heart failure and a reduced ejection fraction: insights from the FIGHT trial. View Abstract
Vaccination Trends in Patients With Heart Failure: Insights From Get With The Guidelines-Heart Failure. View Abstract
Return of Research Results to Study Participants: Uncharted and Untested. View Abstract
Relation of Volume Overload to Clinical Outcomes in Acute Heart Failure (From ASCEND-HF). View Abstract
2018 ACC/HRS/NASCI/SCAI/SCCT Expert Consensus Document on Optimal Use of Ionizing Radiation in Cardiovascular Imaging-Best Practices for Safety and Effectiveness, Part 2: Radiological Equipment Operation, Dose-Sparing Methodologies, Patient and Medical Personnel Protection. View Abstract
2018 ACC/HRS/NASCI/SCAI/SCCT Expert Consensus Document on Optimal Use of Ionizing Radiation in Cardiovascular Imaging-Best Practices for Safety and Effectiveness, Part 1: Radiation Physics and Radiation Biology: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways Developed in Collaboration With Mended Hearts. View Abstract
2018 ACC/HRS/NASCI/SCAI/SCCT Expert Consensus Document on Optimal Use of Ionizing Radiation in Cardiovascular Imaging: Best Practices for Safety and Effectiveness. View Abstract
Circulating Cardiac Troponin I Levels Measured by a Novel Highly Sensitive Assay in Acute Decompensated Heart Failure: Insights From the ASCEND-HF Trial. View Abstract
Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry. View Abstract
Review: In noncardiac surgery, amiodarone, ß-blocker, or statin prophylaxis reduces postoperative AF. View Abstract
Diabetes and long-term outcomes of ischaemic stroke: findings from Get With The Guidelines-Stroke. View Abstract
Association of the Affordable Care Act's Medicaid Expansion With Care Quality and Outcomes for Low-Income Patients Hospitalized With Heart Failure. View Abstract
Harmony Outcomes: A randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus-Rationale, design, and baseline characteristics. View Abstract
Home-Time After Discharge Among Patients Hospitalized With Heart Failure. View Abstract
Characteristics and Treatments of Patients Enrolled in the CHAMP-HF Registry Compared With Patients Enrolled in the PARADIGM-HF Trial. View Abstract
Maximizing benefits and mitigating risks with mineralocorticoid receptor antagonist therapy. View Abstract
The Call for Precision Health Trials in Older Adults: One Size Does Not Fit All. View Abstract
Health Status Disparities by Sex, Race/Ethnicity, and Socioeconomic Status in Outpatients With Heart Failure. View Abstract
Association of Hospital Performance Based on 30-Day Risk-Standardized Mortality Rate With Long-term Survival After Heart Failure Hospitalization: An Analysis of the Get With The Guidelines-Heart Failure Registry. View Abstract
Trends in Noncardiovascular Comorbidities Among Patients Hospitalized for Heart Failure: Insights From the Get With The Guidelines-Heart Failure Registry. View Abstract
High-dose influenza vaccine to reduce clinical outcomes in high-risk cardiovascular patients: Rationale and design of the INVESTED trial. View Abstract
Sustained sex-based treatment differences in acute coronary syndrome care: Insights from the American Heart Association Get With The Guidelines Coronary Artery Disease Registry. View Abstract
Leveraging electronic health records for clinical research. View Abstract
Association of Anemia with Venous Thromboembolism in Acutely Ill Hospitalized Patients: An APEX Trial Substudy. View Abstract
Medicare Expenditures by Race/Ethnicity After Hospitalization for Heart Failure With Preserved Ejection Fraction. View Abstract
Early Ambulation Among Hospitalized Heart Failure Patients Is Associated With Reduced Length of Stay and 30-Day Readmissions. View Abstract
Timing of Postdischarge Follow-Up and Medication Adherence Among Patients With Heart Failure. View Abstract
Health Status Variation Across Practices in Outpatients With Heart Failure: Insights From the CHAMP-HF (Change the Management of Patients With Heart Failure) Registry. View Abstract
Association of Electronic Health Record Use With Quality of Care and Outcomes in Heart Failure: An Analysis of Get With The Guidelines-Heart Failure. View Abstract
Paving a Better Path for Patients Dying of Heart Disease. View Abstract
Is Time of the Essence? The Impact of Time of Hospital Presentation in Acute Heart Failure: Insights From ASCEND-HF Trial. View Abstract
Diastolic Dysfunction in Individuals With Human Immunodeficiency Virus Infection: Literature Review, Rationale and Design of the Characterizing Heart Function on Antiretroviral Therapy (CHART) Study. View Abstract
Determinants of Diuretic Responsiveness and Associated Outcomes During Acute Heart Failure Hospitalization: An Analysis From the NHLBI Heart Failure Network Clinical Trials. View Abstract
Intra-Aortic Balloon Pump Use Before Left Ventricular Assist Device Implantation: Insights From the INTERMACS Registry. View Abstract
Trends and outcomes of cardiac transplantation from donors dying of drug intoxication. View Abstract
Association of Intracerebral Hemorrhage Among Patients Taking Non-Vitamin K Antagonist vs Vitamin K Antagonist Oral Anticoagulants With In-Hospital Mortality. View Abstract
Interaction of Body Mass Index on the Association Between N-Terminal-Pro-b-Type Natriuretic Peptide and Morbidity and Mortality in Patients With Acute Heart Failure: Findings From ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure). View Abstract
Early impact of guideline publication on angiotensin-receptor neprilysin inhibitor use among patients hospitalized for heart failure. View Abstract
Worsening Renal Function in Patients With Acute Heart Failure Undergoing Aggressive Diuresis Is Not Associated With Tubular Injury. View Abstract
Rationale and design of the comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial. View Abstract
Permanent pacemaker use among patients with heart failure and preserved ejection fraction: Findings from the Acute Decompensated Heart Failure National Registry (ADHERE) National Registry. View Abstract
A Hospital Level Analysis of 30-Day Readmission Performance for Heart Failure Patients and Long-Term Survival: Findings from Get With The Guidelines-Heart Failure. View Abstract
Association of D-dimer Levels with Clinical Event Rates and the Efficacy of Betrixaban versus Enoxaparin in the APEX Trial. View Abstract
Extended-Duration Betrixaban Reduces the Risk of Rehospitalization Associated With Venous Thromboembolism Among Acutely Ill Hospitalized Medical Patients: Findings From the APEX Trial (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban Trial). View Abstract
Association of the Hospital Readmissions Reduction Program Implementation With Readmission and Mortality Outcomes in Heart Failure. View Abstract
Increased benefit of betrixaban among patients with a history of venous thromboembolism: a post-hoc analysis of the APEX trial. View Abstract
Assessing Frailty in Patients Undergoing Destination Therapy Left Ventricular Assist Device: Observations from Interagency Registry for Mechanically Assisted Circulatory Support. View Abstract
Symptomatic event reduction with extended-duration betrixaban in acute medically ill hospitalized patients. View Abstract
Use of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Comorbid Diabetes Mellitus or Chronic Kidney Disease. View Abstract
Sudden cardiac death after acute heart failure hospital admission: insights from ASCEND-HF. View Abstract
Primary graft dysfunction after heart transplantation: Incidence, trends, and associated risk factors. View Abstract
Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. View Abstract
Thrombus Burden of Deep Vein Thrombosis and Its Association with Thromboprophylaxis and D-Dimer Measurement: Insights from the APEX Trial. View Abstract
Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction: 5-Year Outcomes. View Abstract
N-terminal pro-B-type natriuretic peptide and the risk of stroke among patients hospitalized with acute heart failure: an APEX trial substudy. View Abstract
When Should Patients Be Involved in Cardiovascular Clinical Trial Design?: Always, Early, and Often. View Abstract
Aetiology, timing and clinical predictors of early vs. late readmission following index hospitalization for acute heart failure: insights from ASCEND-HF. View Abstract
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator: The VICTORIA Trial. View Abstract
Data Sharing and Embedded Research. View Abstract
Pragmatic clinical trials embedded in healthcare systems: generalizable lessons from the NIH Collaboratory. View Abstract
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. View Abstract
2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. View Abstract
How Medicine Has Changed the End of Life for Patients With Cardiovascular Disease. View Abstract
Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial. View Abstract
Representativeness of Medicare Participants in the Jackson Heart Study for African American Medicare Beneficiaries. View Abstract
Competing risk analysis in a large cardiovascular clinical trial: An APEX substudy. View Abstract
Leveraging Behavioral Economics to Improve Heart Failure Care and Outcomes. View Abstract
Role of Volume Redistribution in the Congestion of Heart Failure. View Abstract
Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy. View Abstract
The IMPROVEDD VTE Risk Score: Incorporation of D-Dimer into the IMPROVE Score to Improve Venous Thromboembolism Risk Stratification. View Abstract
Hospitalization for Recently Diagnosed Versus Worsening Chronic Heart Failure: From the ASCEND-HF Trial. View Abstract
Enhancing Insights into Pulmonary Vascular Disease through a Precision Medicine Approach. A Joint NHLBI-Cardiovascular Medical Research and Education Fund Workshop Report. View Abstract
Improving heart failure health: is there a secret Swedish sauce? View Abstract
Integrating Research With Clinical Practice: Keeping It Simple. View Abstract
Accelerometer-Measured Daily Activity in Heart Failure With Preserved Ejection Fraction: Clinical Correlates and Association With Standard Heart Failure Severity Indices. View Abstract
Scope of Sacubitril/Valsartan Eligibility After Heart Failure Hospitalization: Findings From the GWTG-HF Registry (Get With The Guidelines-Heart Failure). View Abstract
Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency: The IRONOUT HF Randomized Clinical Trial. View Abstract
An Initial Evaluation of the Impact of Pokémon GO on Physical Activity. View Abstract
Race/Ethnic Differences in Outcomes Among Hospitalized Medicare Patients With Heart Failure and Preserved Ejection Fraction. View Abstract
Impact of Current Versus Previous Cardiac Resynchronization Therapy Guidelines on the Proportion of Patients With Heart Failure Eligible for Therapy. View Abstract
Cardiovascular events and hospital resource utilization pre- and post-transcatheter mitral valve repair in high-surgical risk patients. View Abstract
Change the management of patients with heart failure: Rationale and design of the CHAMP-HF registry. View Abstract
Engagement, Research, and Evidence: Leveraging the National Patient-Centered Clinical Research Network for Better Cardiovascular Health. View Abstract
Trajectory of Congestion Metrics by Ejection Fraction in Patients With Acute Heart Failure (from the Heart Failure Network). View Abstract
Utilization of cardiac resynchronization therapy in eligible patients hospitalized for heart failure and its association with patient outcomes. View Abstract
Early Adoption of Sacubitril/Valsartan for Patients With Heart Failure With Reduced Ejection Fraction: Insights From Get With the Guidelines-Heart Failure (GWTG-HF). View Abstract
When academic research organizations and clinical research organizations disagree: Processes to minimize discrepancies prior to unblinding of randomized trials. View Abstract
Characterization of hemodynamically stable acute heart failure patients requiring a critical care unit admission: Derivation, validation, and refinement of a risk score. View Abstract
Association of Preceding Antithrombotic Treatment With Acute Ischemic Stroke Severity and In-Hospital Outcomes Among Patients With Atrial Fibrillation. View Abstract
Acute Heart Failure: Alternatives to Hospitalization. View Abstract
Impaired left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: insights from the RELAX trial. View Abstract
Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). View Abstract
Initiation, Continuation, or Withdrawal of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers and Outcomes in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction. View Abstract
Healthcare Resource Availability, Quality of Care, and Acute Ischemic Stroke Outcomes. View Abstract
Factors Associated With and Prognostic Implications of Cardiac Troponin Elevation in Decompensated Heart Failure With Preserved Ejection Fraction: Findings From the American Heart Association Get With The Guidelines-Heart Failure Program. View Abstract
Prediction of 30-Day All-Cause Readmissions in Patients Hospitalized for Heart Failure: Comparison of Machine Learning and Other Statistical Approaches. View Abstract
Can Vaccinations Improve Heart Failure Outcomes?: Contemporary Data and Future Directions. View Abstract
Resting Heart Rate and Long-term Outcomes Among the African American Population: Insights From the Jackson Heart Study. View Abstract
Use of Intravenous Recombinant Tissue Plasminogen Activator in Patients With Acute Ischemic Stroke Who Take Non-Vitamin K Antagonist Oral Anticoagulants Before Stroke. View Abstract
Impact of an Expanded Hospital Recognition Program for Stroke Quality of Care. View Abstract
Response by Hess et al to Letter Regarding Article, "Sex and Race/Ethnicity Differences in Implantable Cardioverter-Defibrillator Counseling and Use Among Patients Hospitalized With Heart Failure: Findings From the Get With The Guidelines-Heart Failure Program". View Abstract
Use of Strategies to Improve Door-to-Needle Times With Tissue-Type Plasminogen Activator in Acute Ischemic Stroke in Clinical Practice: Findings from Target: Stroke. View Abstract
Body Weight Change During and After Hospitalization for Acute Heart Failure: Patient Characteristics, Markers of Congestion, and Outcomes: Findings From the ASCEND-HF Trial. View Abstract
Making Every Mobile Heart Count! View Abstract
Characterization of Mineralocorticoid Receptor Antagonist Therapy Initiation in High-Risk Patients With Heart Failure. View Abstract
Renal Dysfunction Is Associated With Poststroke Discharge Disposition and In-Hospital Mortality: Findings From Get With The Guidelines-Stroke. View Abstract
The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial. View Abstract
Prescription of Guideline-Recommended Implantable Cardioverter Defibrillator and Cardiac Resynchronization Therapy Among Patients Hospitalized With Heart Failure and Varying Degrees of Renal Function. View Abstract
Associations Between Blood Pressure and Outcomes Among Blacks in the Jackson Heart Study. View Abstract
Association of 30-Day Readmission Metric for Heart Failure Under the Hospital Readmissions Reduction Program With Quality of Care and Outcomes. View Abstract
Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients: An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban). View Abstract
Treatment With Tissue Plasminogen Activator in the Golden Hour and the Shape of the 4.5-Hour Time-Benefit Curve in the National United States Get With The Guidelines-Stroke Population. View Abstract
Left Atrial Structure and Function in Heart Failure with Preserved Ejection Fraction: A RELAX Substudy. View Abstract
Management of newly treated diabetes in Medicare beneficiaries with and without heart failure. View Abstract
Guideline-Appropriate Care and In-Hospital Outcomes in Patients With Heart Failure in Teaching and Nonteaching Hospitals: Findings From Get With The Guidelines-Heart Failure. View Abstract
The Changing Landscape of Randomized Clinical Trials in Cardiovascular Disease. View Abstract
Temporal Trends in Care and Outcomes of Patients Receiving Fibrinolytic Therapy Compared to Primary Percutaneous Coronary Intervention: Insights From the Get With The Guidelines Coronary Artery Disease (GWTG-CAD) Registry. View Abstract
Insufficient reduction in heart rate during hospitalization despite beta-blocker treatment in acute decompensated heart failure: insights from the ASCEND-HF trial. View Abstract
Hospital Variation in Home-Time After Acute Ischemic Stroke: Insights From the PROSPER Study (Patient-Centered Research Into Outcomes Stroke Patients Prefer and Effectiveness Research). View Abstract
Pulmonary Hypertension in the Era of Mechanical Circulatory Support. View Abstract
Potential Mortality Reduction With Optimal Implementation of Angiotensin Receptor Neprilysin Inhibitor Therapy in Heart Failure. View Abstract
Influence of Clinical Trial Site Enrollment on Patient Characteristics, Protocol Completion, and End Points: Insights From the ASCEND-HF Trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure). View Abstract
The Potential Impact of Expanding Cardiac Rehabilitation in Heart Failure. View Abstract
Temporal trends and factors associated with diabetes mellitus among patients hospitalized with heart failure: Findings from Get With The Guidelines-Heart Failure registry. View Abstract
Acute management of stroke patients taking non-vitamin K antagonist oral anticoagulants Addressing Real-world Anticoagulant Management Issues in Stroke (ARAMIS) Registry: Design and rationale. View Abstract
Rationale and Design of the ATHENA-HF Trial: Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy in Heart Failure. View Abstract
Sex and Race/Ethnicity Differences in Implantable Cardioverter-Defibrillator Counseling and Use Among Patients Hospitalized With Heart Failure: Findings from the Get With The Guidelines-Heart Failure Program. View Abstract
Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. View Abstract
The ADAPTABLE Trial and Aspirin Dosing in Secondary Prevention for Patients with Coronary Artery Disease. View Abstract
Metabolomic Profiling Identifies Novel Circulating Biomarkers of Mitochondrial Dysfunction Differentially Elevated in Heart Failure With Preserved Versus Reduced Ejection Fraction: Evidence for Shared Metabolic Impairments in Clinical Heart Failure. View Abstract
Amiodarone use in patients listed for heart transplant is associated with increased 1-year post-transplant mortality. View Abstract
Antihyperglycemic Medication Use Among Medicare Beneficiaries With Heart Failure, Diabetes Mellitus, and Chronic Kidney Disease. View Abstract
Combined neprilysin and renin-angiotensin system inhibition in heart failure with reduced ejection fraction: a meta-analysis. View Abstract
Development and validation of a risk model for in-hospital worsening heart failure from the Acute Decompensated Heart Failure National Registry (ADHERE). View Abstract
Response to Letter Regarding Article, "Temporal Trends and Variation in Early Scheduled Follow-up After a Hospitalization for Heart Failure: Findings from Get With The Guidelines-Heart Failure. View Abstract
Trends in 30-Day Readmission Rates for Patients Hospitalized With Heart Failure: Findings From the Get With The Guidelines-Heart Failure Registry. View Abstract
Precipitating Clinical Factors, Heart Failure Characterization, and Outcomes in Patients Hospitalized With Heart Failure With Reduced, Borderline, and Preserved Ejection Fraction. View Abstract
Comparative Effectiveness of Cardiac Resynchronization Therapy Among Patients With Heart Failure and Atrial Fibrillation: Findings From the National Cardiovascular Data Registry's Implantable Cardioverter-Defibrillator Registry. View Abstract
Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients. View Abstract
Trends in the Use of Guideline-Directed Therapies Among Dialysis Patients Hospitalized With Systolic Heart Failure: Findings From the American Heart Association Get With The Guidelines-Heart Failure Program. View Abstract
Oral Iron Therapy for Heart Failure With Reduced Ejection Fraction: Design and Rationale for Oral Iron Repletion Effects on Oxygen Uptake in Heart Failure. View Abstract
Response to Letter Regarding Article, "Comparative Effectiveness of Implantable Cardioverter Defibrillators for Primary Prevention in Women". View Abstract
Finerenone in heart failure: walking a fine line. View Abstract
Association of Get With The Guidelines-Stroke Program Participation and Clinical Outcomes for Medicare Beneficiaries With Ischemic Stroke. View Abstract
TRENDS IN THE CARE AND OUTCOMES OF MEDICARE BENEFICIARIES WITH TYPE 2 DIABETES, 2002-2011. View Abstract
Post-discharge Follow-up Characteristics Associated With 30-Day Readmission After Heart Failure Hospitalization. View Abstract
Geographic Differences in Patients in a Global Acute Heart Failure Clinical Trial (from the ASCEND-HF Trial). View Abstract
Arrival by ambulance in acute heart failure: insights into the mode of presentation from Acute Studies of Nesiritide in Decompensated Heart Failure (ASCEND-HF). View Abstract
The Obesity and Heart Failure Epidemics Among African Americans: Insights From the Jackson Heart Study. View Abstract
Dichotomous Relationship Between Age and 30-Day Death or Rehospitalization in Heart Failure Patients Admitted With Acute Decompensated Heart Failure: Results From the ASCEND-HF Trial. View Abstract
Assessment of Home-Time After Acute Ischemic Stroke in Medicare Beneficiaries. View Abstract
Has Public Reporting of Hospital Readmission Rates Affected Patient Outcomes?: Analysis of Medicare Claims Data. View Abstract
Good Clinical Practice Guidance and Pragmatic Clinical Trials: Balancing the Best of Both Worlds. View Abstract
Use of Heart Failure Medical Therapies Among Patients With Left Ventricular Assist Devices: Insights From INTERMACS. View Abstract
Temporal Trends of Digoxin Use in Patients Hospitalized With Heart Failure: Analysis From the American Heart Association Get With The Guidelines-Heart Failure Registry. View Abstract
Sex and Race/Ethnicity-Related Disparities in Care and Outcomes After Hospitalization for Coronary Artery Disease Among Older Adults. View Abstract
Clinical Effectiveness of Hydralazine-Isosorbide Dinitrate Therapy in Patients With Heart Failure and Reduced Ejection Fraction: Findings From the Get With The Guidelines-Heart Failure Registry. View Abstract
Nesiritide in patients hospitalized for acute heart failure: does timing matter? Implication for future acute heart failure trials. View Abstract
Serum Bicarbonate in Acute Heart Failure: Relationship to Treatment Strategies and Clinical Outcomes. View Abstract
Trends and outcomes of patients with adult congenital heart disease and pulmonary hypertension listed for orthotopic heart transplantation in the United States. View Abstract
Temporal Trends and Variation in Early Scheduled Follow-Up After a Hospitalization for Heart Failure: Findings from Get With The Guidelines-Heart Failure. View Abstract
Risks and Benefits Associated With Prestroke Antiplatelet Therapy Among Patients With Acute Ischemic Stroke Treated With Intravenous Tissue Plasminogen Activator. View Abstract
Comparative Effectiveness of Implantable Cardioverter Defibrillators for Primary Prevention in Women. View Abstract
Relation of Elevated Heart Rate in Patients With Heart Failure With Reduced Ejection Fraction to One-Year Outcomes and Costs. View Abstract
Liver function tests in patients with acute heart failure and associated outcomes: insights from ASCEND-HF. View Abstract
Evaluation of Novel Metrics of Symptom Relief in Acute Heart Failure: The Worst Symptom Score. View Abstract
Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial. View Abstract
Discharge heart rate and ß-blocker dose in patients hospitalized with heart failure: Findings from the OPTIMIZE-HF registry. View Abstract
Statin use, intensity, and 3-year clinical outcomes among older patients with coronary artery disease. View Abstract
Comparative Effectiveness of CRT-D Versus Defibrillator Alone in HF Patients With Moderate-to-Severe Chronic Kidney Disease. View Abstract
Increased mortality with elevated plasma endothelin-1 in acute heart failure: an ASCEND-HF biomarker substudy. View Abstract
Sex Differences in the Management and Outcomes of Heart Failure With Preserved Ejection Fraction in Patients Presenting to the Emergency Department With Acute Heart Failure. View Abstract
Association of Arterial Pulse Pressure With Long-Term Clinical Outcomes in Patients With Heart Failure. View Abstract
Prognostic Value of Baseline and Changes in Circulating Soluble ST2 Levels and the Effects of Nesiritide in Acute Decompensated Heart Failure. View Abstract
Torsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial). View Abstract
Depressive Symptoms and Risk of Cardiovascular Events in Blacks: Findings From the Jackson Heart Study. View Abstract
Consistency of Laboratory Monitoring During Initiation of Mineralocorticoid Receptor Antagonist Therapy in Patients With Heart Failure. View Abstract
Cardiac transplantation for older patients: Characteristics and outcomes in the septuagenarian population. View Abstract
Evaluation of a provocative dyspnea severity score in acute heart failure. View Abstract
The clinical course of health status and association with outcomes in patients hospitalized for heart failure: insights from ASCEND-HF. View Abstract
Characteristics, Treatments, and Outcomes of Hospitalized Heart Failure Patients Stratified by Etiologies of Cardiomyopathy. View Abstract
Quality of Care and Ischemic Stroke Risk After Hospitalization for Transient Ischemic Attack: Findings From Get With The Guidelines-Stroke. View Abstract
Smoking Paradox in Patients Hospitalized With Coronary Artery Disease or Acute Ischemic Stroke: Findings From Get With The Guidelines. View Abstract
Circulating Kidney Injury Molecule-1 Levels in Acute Heart Failure: Insights From the ASCEND-HF Trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure). View Abstract
Differences in health care use and outcomes by the timing of in-hospital worsening heart failure. View Abstract
What's Harder: Seeing a Doctor or Reducing Readmissions? View Abstract
Extended-Duration Thromboprophylaxis Among Acute Medically Ill Patients: An Unmet Need. View Abstract
Medication Initiation Burden Required to Comply With Heart Failure Guideline Recommendations and Hospital Quality Measures. View Abstract
Temporal Trends and Factors Associated With Cardiac Rehabilitation Referral Among Patients Hospitalized With Heart Failure: Findings From Get With The Guidelines-Heart Failure Registry. View Abstract
The ADAPTABLE Trial and PCORnet: Shining Light on a New Research Paradigm. View Abstract
Acute Heart Failure and Atrial Fibrillation: Insights From the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF) Trial. View Abstract
Association Between Comorbidities and Outcomes in Heart Failure Patients With and Without an Implantable Cardioverter-Defibrillator for Primary Prevention. View Abstract
Clinical Effectiveness of Statin Therapy After Ischemic Stroke: Primary Results From the Statin Therapeutic Area of the Patient-Centered Research Into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) Study. View Abstract
Measuring heart failure quality: does perfection matter? View Abstract
Real world effectiveness of warfarin among ischemic stroke patients with atrial fibrillation: observational analysis from Patient-Centered Research into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) study. View Abstract
Intensification of Medication Therapy for Cardiorenal Syndrome in Acute Decompensated Heart Failure. View Abstract
Cluster-Randomized Trial of Personalized Site Performance Feedback in Get With The Guidelines-Heart Failure. View Abstract
Assessing the Quality and Comparative Effectiveness of Team-Based Care for Heart Failure: Who, What, Where, When, and How. View Abstract
Novel Oral Anticoagulant Use Among Patients With Atrial Fibrillation Hospitalized With Ischemic Stroke or Transient Ischemic Attack. View Abstract
Heart Failure in Non-Caucasians, Women, and Older Adults: A White Paper on Special Populations From the Heart Failure Society of America Guideline Committee. View Abstract
Relief and Recurrence of Congestion During and After Hospitalization for Acute Heart Failure: Insights From Diuretic Optimization Strategy Evaluation in Acute Decompensated Heart Failure (DOSE-AHF) and Cardiorenal Rescue Study in Acute Decompensated Heart Failure (CARESS-HF). View Abstract
Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C. View Abstract
Comparison of 2-Year Outcomes of Extended Criteria Cardiac Transplantation Versus Destination Left Ventricular Assist Device Therapy Using Continuous Flow. View Abstract
Lack of impact of electronic health records on quality of care and outcomes for ischemic stroke. View Abstract
Diuretic response in acute heart failure-an analysis from ASCEND-HF. View Abstract
Advanced (stage D) heart failure: a statement from the Heart Failure Society of America Guidelines Committee. View Abstract
Heart rate at hospital discharge in patients with heart failure is associated with mortality and rehospitalization. View Abstract
ACP Journal Club: pooled RCTs: ß-blockers reduce mortality in heart failure patients with sinus rhythm but not in those with AF. View Abstract
Patient-Centered Research into Outcomes Stroke Patients Prefer and Effectiveness Research: Implementing the patient-driven research paradigm to aid decision making in stroke care. View Abstract
Worsening heart failure during hospitalization for acute heart failure: Insights from the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF). View Abstract
Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study. View Abstract
Predictors of clinical outcomes in acute decompensated heart failure: Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure outcome models. View Abstract
Characteristics, quality of care, and in-hospital outcomes of Asian-American heart failure patients: Findings from the American Heart Association Get With The Guidelines-Heart Failure Program. View Abstract
Same-day discharge and risks of mortality and readmission after elective ICD placement for primary prevention. View Abstract
Utility of socioeconomic status in predicting 30-day outcomes after heart failure hospitalization. View Abstract
Implementation of management strategies for diabetes and hypertension: from local to global health in cardiovascular diseases. View Abstract
Trends in endovascular therapy and clinical outcomes within the nationwide Get With The Guidelines-Stroke registry. View Abstract
Loop diuretic dose adjustments after a hospitalization for heart failure: insights from ASCEND-HF. View Abstract
Results of the Chronic Heart Failure Intervention to Improve MEdication Adherence study: A randomized intervention in high-risk patients. View Abstract
Correlation between peak expiratory flow rate and NT-proBNP in patients with acute heart failure. An analysis from ASCEND-HF trial. View Abstract
Ventricular conduction and long-term heart failure outcomes and mortality in African Americans: insights from the Jackson Heart Study. View Abstract
In heart failure, automatic implant-based telemonitoring reduced a composite of cardiac events and mortality. View Abstract
Temporal trends for secondary prevention measures among patients hospitalized with coronary artery disease. View Abstract
Effects of left ventricular assist device support on biomarkers of cardiovascular stress, fibrosis, fluid homeostasis, inflammation, and renal injury. View Abstract
Clinical commentary on "Certain uncertainty: life after stroke from the patient's perspective". View Abstract
Comparative assessment of short-term adverse events in acute heart failure with cystatin C and other estimates of renal function: results from the ASCEND-HF trial. View Abstract
The association between meteorological events and acute heart failure: new insights from ASCEND-HF. View Abstract
Primary prevention implantable cardioverter-defibrillators and survival in older women. View Abstract
Acute decompensated heart failure patients admitted to critical care units: insights from ASCEND-HF. View Abstract
Decongestion strategies and renin-angiotensin-aldosterone system activation in acute heart failure. View Abstract
Long-term clinical and angiographic outcomes in patients with diabetes undergoing coronary artery bypass graft surgery: results from the Project of Ex-vivo Vein Graft Engineering via Transfection IV trial. View Abstract
Chest pain in patients with heart failure: why history may matter. View Abstract
Short- and long-term rehospitalization and mortality for heart failure in 4 racial/ethnic populations. View Abstract
Relation of dyspnea severity on admission for acute heart failure with outcomes and costs. View Abstract
Effect of serelaxin on mode of death in acute heart failure: results from the RELAX-AHF study. View Abstract
Guideline-directed low-density lipoprotein management in high-risk patients with ischemic stroke: findings from Get with the Guidelines-Stroke 2003 to 2012. View Abstract
Hypotension during hospitalization for acute heart failure is independently associated with 30-day mortality: findings from ASCEND-HF. View Abstract
Chronic kidney disease and bleeding complications after intravenous thrombolytic therapy for acute ischemic stroke. View Abstract
Recognition of biomarker identified high-risk patients in the acute medically ill venous thromboembolism prevention with extended duration betrixaban study resulting in a protocol amendment. View Abstract
Transient and persistent worsening renal function during hospitalization for acute heart failure. View Abstract
Clinical effectiveness of cardiac resynchronization therapy versus medical therapy alone among patients with heart failure: analysis of the ICD Registry and ADHERE. View Abstract
Racial/Ethnic differences in process of care and outcomes among patients hospitalized with intracerebral hemorrhage. View Abstract
Impact of an expanded hospital recognition program for heart failure quality of care. View Abstract
Associations between anticoagulation therapy and risks of mortality and readmission among patients with heart failure and atrial fibrillation. View Abstract
Hospitalized hemorrhagic stroke patients with renal insufficiency: clinical characteristics, care patterns, and outcomes. View Abstract
Cardiovascular phenotype in HFpEF patients with or without diabetes: a RELAX trial ancillary study. View Abstract
Adherence to Third European Cooperative Acute Stroke Study 3- to 4.5-hour exclusions and association with outcome: data from Get with the Guidelines-Stroke. View Abstract
Nesiritide, renal function, and associated outcomes during hospitalization for acute decompensated heart failure: results from the Acute Study of Clinical Effectiveness of Nesiritide and Decompensated Heart Failure (ASCEND-HF). View Abstract
Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population. View Abstract
Characteristics and outcomes of patients with heart failure and discordant findings by right-sided heart catheterization and cardiopulmonary exercise testing. View Abstract
In-hospital worsening heart failure and associations with mortality, readmission, and healthcare utilization. View Abstract
GLP-1 agonist therapy for advanced heart failure with reduced ejection fraction: design and rationale for the functional impact of GLP-1 for heart failure treatment study. View Abstract
Current quality of cardiovascular prevention for Million Hearts: an analysis of 147,038 outpatients from The Guideline Advantage. View Abstract
Patterns of care quality and prognosis among hospitalized ischemic stroke patients with chronic kidney disease. View Abstract
Association between prophylactic implantable cardioverter-defibrillators and survival in patients with left ventricular ejection fraction between 30% and 35%. View Abstract
Resting ventricular-vascular function and exercise capacity in heart failure with preserved ejection fraction: a RELAX trial ancillary study. View Abstract
Comparative effectiveness of cardiac resynchronization therapy with an implantable cardioverter-defibrillator versus defibrillator therapy alone: a cohort study. View Abstract
Strategies used by hospitals to improve speed of tissue-type plasminogen activator treatment in acute ischemic stroke. View Abstract
Door-to-needle times for tissue plasminogen activator administration and clinical outcomes in acute ischemic stroke before and after a quality improvement initiative. View Abstract
Digoxin initiation is associated with lower risk of all-cause readmission after hospitalisation for heart failure. View Abstract
Prevalence and predictors of nonobstructive coronary artery disease identified with coronary angiography in contemporary clinical practice. View Abstract
Representativeness of RELAX-AHF clinical trial population in acute heart failure. View Abstract
Response to Relationship of race/ethnicity with door-to-balloon time and mortality in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: Findings from Get With the Guidelines-Coronary Artery Diseases. Authors' reply. View Abstract
Use of renin-angiotensin system blockers in acute coronary syndromes: findings from Get With the Guidelines-Coronary Artery Disease Program. View Abstract
High-sensitivity C-reactive protein in acute heart failure: insights from the ASCEND-HF trial. View Abstract
Hospital variation in intravenous inotrope use for patients hospitalized with heart failure: insights from Get With The Guidelines. View Abstract
Trends in the use and outcomes of ventricular assist devices among medicare beneficiaries, 2006 through 2011. View Abstract
Outcomes of medicare beneficiaries with heart failure and atrial fibrillation. View Abstract
Quality of care for patients with acute coronary syndromes as a function of hospital revascularization capability: Insights from get with the guidelines-CAD. View Abstract
Peripheral arterial testing before lower extremity amputation among Medicare beneficiaries, 2000 to 2010. View Abstract
Prescribing warfarin at discharge for heart failure patients: findings from the Get With The Guidelines-Heart Failure Registry. View Abstract
Temporal trends in clinical characteristics of patients without known cardiovascular disease with a first episode of myocardial infarction. View Abstract
Valvular heart disease in patients supported with left ventricular assist devices. View Abstract
Anticoagulation and Clinical Outcomes in Heart Failure Patients With Atrial Fibrillation: Findings From the ADHERE Registry. View Abstract
Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. View Abstract
Management of postoperative atrial fibrillation and subsequent outcomes in contemporary patients undergoing cardiac surgery: insights from the Society of Thoracic Surgeons CAPS-Care Atrial Fibrillation Registry. View Abstract
Thrombolytic therapy for thrombosis of continuous flow ventricular assist devices. View Abstract
The relationship between left ventricular ejection fraction and mortality in patients with acute heart failure: insights from the ASCEND-HF Trial. View Abstract
Combined use of warfarin and oral P2Y12 inhibitors in patients with atrial fibrillation and acute coronary syndrome. View Abstract
Associations between atrial fibrillation and early outcomes of patients with heart failure and reduced or preserved ejection fraction. View Abstract
The design and rationale for the Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban (APEX) study. View Abstract
Clinical course of atrial fibrillation in older adults: the importance of cardiovascular events beyond stroke. View Abstract
Adherence and persistence in the use of warfarin after hospital discharge among patients with heart failure and atrial fibrillation. View Abstract
A crisis of the heart: an acute reversible cardiomyopathy bridged to recovery in a patient with Addison's disease. View Abstract
Synthesizing lessons learned from get with the guidelines: the value of disease-based registries in improving quality and outcomes. View Abstract
Impact of atrial fibrillation on exercise capacity in heart failure with preserved ejection fraction: a RELAX trial ancillary study. View Abstract
Differences in treatment, outcomes, and quality of life among patients with heart failure in Canada and the United States. View Abstract
Relationship between sex, ejection fraction, and B-type natriuretic peptide levels in patients hospitalized with heart failure and associations with inhospital outcomes: findings from the Get With The Guideline-Heart Failure Registry. View Abstract
Comparison of performance achievement award recognition with primary stroke center certification for acute ischemic stroke care. View Abstract
Ten-year experience with extended criteria cardiac transplantation. View Abstract
Postdischarge international normalized ratio testing and long-term clinical outcomes of patients with heart failure receiving warfarin: findings from the ADHERE registry linked to Medicare claims. View Abstract
Racial differences in the prevalence and outcomes of atrial fibrillation among patients hospitalized with heart failure. View Abstract
Relationship of race/ethnicity with door-to-balloon time and mortality in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: findings from Get With the Guidelines-Coronary Artery Disease. View Abstract
Associations between use of the hospitalist model and quality of care and outcomes of older patients hospitalized for heart failure. View Abstract
Who enrolls in the Medicare Part D prescription drug benefit program? Medication use among patients with heart failure. View Abstract
Targeting the kidney in acute heart failure: can old drugs provide new benefit? Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE AHF) trial. View Abstract
Medical resource use, costs, and quality of life in patients with acute decompensated heart failure: findings from ASCEND-HF. View Abstract
Use of hydralazine-isosorbide dinitrate combination in African American and other race/ethnic group patients with heart failure and reduced left ventricular ejection fraction. View Abstract
QRS duration, bundle-branch block morphology, and outcomes among older patients with heart failure receiving cardiac resynchronization therapy. View Abstract
Racial/Ethnic differences in B-type natriuretic peptide levels and their association with care and outcomes among patients hospitalized with heart failure: findings from Get With The Guidelines-Heart Failure. View Abstract
Global variation in quality of care among patients hospitalized with acute heart failure in an international trial: findings from the acute study clinical effectiveness of nesiritide in decompensated heart failure trial (ASCEND-HF). View Abstract
Comparative effectiveness of pharmacotherapies for prevention of atrial fibrillation following coronary artery bypass surgery. View Abstract
Preventing heart failure. View Abstract
Duration of vancomycin treatment for coagulase-negative Staphylococcus sepsis in very low birth weight infants. View Abstract
Xanthine oxidase inhibition for hyperuricemic heart failure patients: design and rationale of the EXACT-HF study. View Abstract
Early intravenous heart failure therapy and outcomes among older patients hospitalized for acute decompensated heart failure: findings from the Acute Decompensated Heart Failure Registry Emergency Module (ADHERE-EM). View Abstract
Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke. View Abstract
Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. View Abstract
Do countries or hospitals with longer hospital stays for acute heart failure have lower readmission rates?: Findings from ASCEND-HF. View Abstract
Effects of nesiritide and predictors of urine output in acute decompensated heart failure: results from ASCEND-HF (acute study of clinical effectiveness of nesiritide and decompensated heart failure). View Abstract
Validated, electronic health record deployable prediction models for assessing patient risk of 30-day rehospitalization and mortality in older heart failure patients. View Abstract
Acute decompensated heart failure: update on new and emerging evidence and directions for future research. View Abstract
Clinical effectiveness of anticoagulation therapy among older patients with heart failure and without atrial fibrillation: findings from the ADHERE registry linked to Medicare claims. View Abstract
Targeting anti-beta-1-adrenergic receptor antibodies for dilated cardiomyopathy. View Abstract
Racial and ethnic differences in outcomes in older patients with acute ischemic stroke. View Abstract
Dysphagia in the setting of left ventricular assist device hemolysis. View Abstract
Patterns of emergency medical services use and its association with timely stroke treatment: findings from Get With the Guidelines-Stroke. View Abstract
Transitional adherence and persistence in the use of aldosterone antagonist therapy in patients with heart failure. View Abstract
Cardiohepatic interactions in heart failure: an overview and clinical implications. View Abstract
Performance measures to promote quality improvement in sudden cardiac arrest prevention and treatment. View Abstract
Are we targeting the right metric for heart failure? Comparison of hospital 30-day readmission rates and total episode of care inpatient days. View Abstract
Exercise training and implantable cardioverter-defibrillator shocks in patients with heart failure: results from HF-ACTION (Heart Failure and A Controlled Trial Investigating Outcomes of Exercise TraiNing). View Abstract
Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. View Abstract
Insurance status and outcome after intracerebral hemorrhage: findings from Get With The Guidelines-stroke. View Abstract
Ultrafiltration in heart failure with cardiorenal syndrome. View Abstract
Priorities for comparative effectiveness reviews in cardiovascular disease. View Abstract
Age differences in the use of implantable cardioverter-defibrillators among older patients hospitalized with heart failure. View Abstract
Admission heart rate and in-hospital outcomes in patients hospitalized for heart failure in sinus rhythm and in atrial fibrillation. View Abstract
Predictors of incident heart failure hospitalizations among patients with impaired glucose tolerance: insight from the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research study. View Abstract
A risk score for in-hospital death in patients admitted with ischemic or hemorrhagic stroke. View Abstract
Dysphagia screening and hospital-acquired pneumonia in patients with acute ischemic stroke: findings from Get with the Guidelines--Stroke. View Abstract
Markers of decongestion, dyspnea relief, and clinical outcomes among patients hospitalized with acute heart failure. View Abstract
Achievement of guideline-concordant care and in-hospital outcomes in patients with coronary artery disease in teaching and nonteaching hospitals: results from the Get With The Guidelines-Coronary Artery Disease program. View Abstract
Associations between aldosterone antagonist therapy and risks of mortality and readmission among patients with heart failure and reduced ejection fraction. View Abstract
In Reply: B-type natriuretic peptide level and postdischarge thrombotic events in older patients hospitalized with heart failure: Insights from the ADHERE registry. View Abstract
Predictors of early dyspnoea relief in acute heart failure and the association with 30-day outcomes: findings from ASCEND-HF. View Abstract
Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system. View Abstract
Ultrafiltration in decompensated heart failure with cardiorenal syndrome. View Abstract
Temporal trends and predictors in the use of aldosterone antagonists post-acute myocardial infarction. View Abstract
Addressing the 100% of heart failure: a call for complete care of all ages. View Abstract
Biomarkers in acutely decompensated heart failure with preserved or reduced ejection fraction. View Abstract
Outcomes associated with warfarin use in older patients with heart failure and atrial fibrillation and a cardiovascular implantable electronic device: findings from the ADHERE registry linked to Medicare claims. View Abstract
Acute heart failure: perspectives from a randomized trial and a simultaneous registry. View Abstract
Outcomes of Medicare beneficiaries undergoing catheter ablation for atrial fibrillation. View Abstract
Completion of guideline-recommended initial evaluation of atrial fibrillation. View Abstract
Are racial/ethnic gaps in the use of cardiac resynchronization therapy narrowing?: an analysis of 107,096 patients from the National Cardiovascular Data Registry's ICD Registry. View Abstract
PhosphdiesteRasE-5 Inhibition to Improve CLinical Status and EXercise Capacity in Diastolic Heart Failure (RELAX) trial: rationale and design. View Abstract
2012 ACCF/AATS/SCAI/STS expert consensus document on transcatheter aortic valve replacement: developed in collabration with the American Heart Association, American Society of Echocardiography, European Association for Cardio-Thoracic Surgery, Heart Failure Society of America, Mended Hearts, Society of Cardiovascular Anesthesiologists, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. View Abstract
Guideline adherence after ST-segment elevation versus non-ST segment elevation myocardial infarction. View Abstract
National survey of hospital strategies to reduce heart failure readmissions: findings from the Get With the Guidelines-Heart Failure registry. View Abstract
Predictors of adherence to performance measures in patients with acute myocardial infarction. View Abstract
Trends in clinical, demographic, and biochemical characteristics of patients with acute myocardial infarction from 2003 to 2008: a report from the american heart association get with the guidelines coronary artery disease program. View Abstract
Patterns, predictors, variations, and temporal trends in emergency medical service hospital prenotification for acute ischemic stroke. View Abstract
Comparison of 30-day mortality models for profiling hospital performance in acute ischemic stroke with vs without adjustment for stroke severity. View Abstract
Risk score for intracranial hemorrhage in patients with acute ischemic stroke treated with intravenous tissue-type plasminogen activator. View Abstract
Troponin I in acute decompensated heart failure: insights from the ASCEND-HF study. View Abstract
Emergency medical service hospital prenotification is associated with improved evaluation and treatment of acute ischemic stroke. View Abstract
Defining heart failure end points in ST-segment elevation myocardial infarction trials: integrating past experiences to chart a path forward. View Abstract
Quality of care and outcomes among patients with acute myocardial infarction by level of kidney function at admission: report from the get with the guidelines coronary artery disease program. View Abstract
Reperfusion strategies and quality of care in 5339 patients age 80 years or older presenting with ST-elevation myocardial infarction: analysis from get with the guidelines-coronary artery disease. View Abstract
Age and gender differences in quality of care and outcomes for patients with ST-segment elevation myocardial infarction. View Abstract
Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator. View Abstract
Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. View Abstract
B-type natriuretic peptide level and postdischarge thrombotic events in older patients hospitalized with heart failure: insights from the Acute Decompensated Heart Failure National Registry. View Abstract
Design and rationale of a retrospective clinical effectiveness study of aldosterone antagonist therapy in patients with heart failure. View Abstract
Times from symptom onset to hospital arrival in the Get with the Guidelines--Stroke Program 2002 to 2009: temporal trends and implications. View Abstract
Pharmacotherapy in Medicare beneficiaries with atrial fibrillation. View Abstract
2012 ACCF/AATS/SCAI/STS expert consensus document on transcatheter aortic valve replacement: developed in collaboration with the American Heart Association, American Society of Echocardiography, European Association for Cardio-Thoracic Surgery, Heart Failure Society of America, Mended Hearts, Society of Cardiovascular Anesthesiologists, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. View Abstract
Assessment of dyspnea in acute decompensated heart failure: insights from ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure) on the contributions of peak expiratory flow. View Abstract
Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee. View Abstract
Utilization of hospice and predicted mortality risk among older patients hospitalized with heart failure: findings from GWTG-HF. View Abstract
International variation in use of oral anticoagulation among heart failure patients with atrial fibrillation. View Abstract
Care and outcomes of Hispanic patients admitted with heart failure with preserved or reduced ejection fraction: findings from get with the guidelines-heart failure. View Abstract
Data quality in the American Heart Association Get With The Guidelines-Stroke (GWTG-Stroke): results from a national data validation audit. View Abstract
Sex differences in in-hospital mortality in acute decompensated heart failure with reduced and preserved ejection fraction. View Abstract
Presence of atrial fibrillation is independently associated with adverse outcomes in patients hospitalized with heart failure: an analysis of get with the guidelines-heart failure. View Abstract
Relationship of national institutes of health stroke scale to 30-day mortality in medicare beneficiaries with acute ischemic stroke. View Abstract
Indications for cardiac resynchronization therapy: 2011 update from the Heart Failure Society of America Guideline Committee. View Abstract
Patient and hospital characteristics associated with traditional measures of inpatient quality of care for patients with heart failure. View Abstract
Trends in use of implantable cardioverter-defibrillator therapy among patients hospitalized for heart failure: have the previously observed sex and racial disparities changed over time? View Abstract
Care and outcomes of Asian-American acute myocardial infarction patients: findings from the American Heart Association Get With The Guidelines-Coronary Artery Disease program. View Abstract
Incidence and prevalence of atrial fibrillation and associated mortality among Medicare beneficiaries, 1993-2007. View Abstract
Get With The Guidelines program participation, process of care, and outcome for Medicare patients hospitalized with heart failure. View Abstract
Trends in smoking cessation counseling: experience from American Heart Association-get with the guidelines. View Abstract
Predicting costs among medicare beneficiaries with heart failure. View Abstract
Prediction is very hard, especially about the future: comment on "factors associated with 30-day readmission rates after percutaneous coronary intervention". View Abstract
Regional differences in clinical profile, quality of care, and outcomes among Hispanic patients hospitalized with acute myocardial infarction in the Get with Guidelines-Coronary Artery Disease (GWTG-CAD) registry. View Abstract
Pharmacologic prophylaxis for venous thromboembolism and 30-day outcomes among older patients hospitalized with heart failure: an analysis from the ADHERE national registry linked to Medicare claims. View Abstract
Mechanisms of bleeding and approach to patients with axial-flow left ventricular assist devices. View Abstract
Changes in myocardial infarction guideline adherence as a function of patient risk: an end to paradoxical care? View Abstract
Comparison of composite measure methodologies for rewarding quality of care: an analysis from the American Heart Association's Get With The Guidelines program. View Abstract
Patient characteristics from a regional multicenter database of acute decompensated heart failure in Asia Pacific (ADHERE International-Asia Pacific). View Abstract
Representativeness of the Get With The Guidelines-Stroke Registry: comparison of patient and hospital characteristics among Medicare beneficiaries hospitalized with ischemic stroke. View Abstract
Payment source, quality of care, and outcomes in patients hospitalized with heart failure. View Abstract
Postoperative inotrope and vasopressor use following CABG: outcome data from the CAPS-care study. View Abstract
Improvement in use of anticoagulation therapy in patients with ischemic stroke: results from Get With The Guidelines-Stroke. View Abstract
Outcomes in mild or rapidly improving stroke not treated with intravenous recombinant tissue-type plasminogen activator: findings from Get With The Guidelines-Stroke. View Abstract
Improving door-to-needle times in acute ischemic stroke: the design and rationale for the American Heart Association/American Stroke Association's Target: Stroke initiative. View Abstract
Advanced heart failure. View Abstract
Quality of care and outcomes in women hospitalized for heart failure. View Abstract
Device therapy in heart failure patients with chronic kidney disease. View Abstract
ACP Journal Club. Review: cardiac resynchronization reduces mortality and hospitalizations in patients with either more or less symptomatic HF. View Abstract
Diabetes, quality of care, and in-hospital outcomes in patients hospitalized with heart failure. View Abstract
The importance of consistent, high-quality acute myocardial infarction and heart failure care results from the American Heart Association's Get with the Guidelines Program. View Abstract
Quality of acute myocardial infarction care and outcomes in 33,997 patients aged 80 years or older: findings from Get With The Guidelines-Coronary Artery Disease (GWTG-CAD). View Abstract
The need for multiple measures of hospital quality: results from the Get with the Guidelines-Heart Failure Registry of the American Heart Association. View Abstract
Associations of patient demographic characteristics and regional physician density with early physician follow-up among medicare beneficiaries hospitalized with heart failure. View Abstract
Admission, discharge, or change in B-type natriuretic peptide and long-term outcomes: data from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF) linked to Medicare claims. View Abstract
Quality of care for sudden cardiac arrest: Proposed steps to improve the translation of evidence into practice. View Abstract
Characterization of heart failure patients with preserved ejection fraction: a comparison between ADHERE-US registry and ADHERE-International registry. View Abstract
Potential impact of optimal implementation of evidence-based heart failure therapies on mortality. View Abstract
Predictors of hospital length of stay in heart failure: findings from Get With the Guidelines. View Abstract
Do heart failure disease management programs make financial sense under a bundled payment system? View Abstract
Patterns and predictors of evidence-based medication continuation among hospitalized heart failure patients (from Get With the Guidelines-Heart Failure). View Abstract
Association of race/ethnicity with clinical risk factors, quality of care, and acute outcomes in patients hospitalized with heart failure. View Abstract
Discharge to a skilled nursing facility and subsequent clinical outcomes among older patients hospitalized for heart failure. View Abstract
Diuretic strategies in patients with acute decompensated heart failure. View Abstract
Use and predictors of heart failure disease management referral in patients hospitalized with heart failure: insights from the Get With the Guidelines Program. View Abstract
Minding the gap between efforts to reduce readmissions and disparities. View Abstract
Systematic review of the incidence of sudden cardiac death in the United States. View Abstract
Timeliness of tissue-type plasminogen activator therapy in acute ischemic stroke: patient characteristics, hospital factors, and outcomes associated with door-to-needle times within 60 minutes. View Abstract
Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: An analysis of 65,396 hospitalizations from 344 hospita participating in Get With The Guidelines (GWTG). View Abstract
Non-evidence-based ICD implantations in the United States. View Abstract
Hospital-level variation in mortality and rehospitalization for medicare beneficiaries with acute ischemic stroke. View Abstract
Incremental value of clinical data beyond claims data in predicting 30-day outcomes after heart failure hospitalization. View Abstract
Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: an analysis of 65,396 hospitalizations from 344 hospitals participating in Get With The Guidelines (GWTG). View Abstract
Combination of loop diuretics with thiazide-type diuretics in heart failure. View Abstract
Generalizability and longitudinal outcomes of a national heart failure clinical registry: Comparison of Acute Decompensated Heart Failure National Registry (ADHERE) and non-ADHERE Medicare beneficiaries. View Abstract
Resource use in the last 6 months of life among medicare beneficiaries with heart failure, 2000-2007. View Abstract
Addressing disparities in sudden cardiac arrest care and the underutilization of effective therapies. View Abstract
Risk score for in-hospital ischemic stroke mortality derived and validated within the Get With the Guidelines-Stroke Program. View Abstract
Patterns and predictors of discharge statin prescription among hospitalized patients with intracerebral hemorrhage. View Abstract
A review of dyspnea in acute heart failure syndromes. View Abstract
Rapid change in prescribing behavior in hospitals participating in get with the guidelines-stroke after release of the management of atherothrombosis with clopidogrel in high-risk patients (MATCH) clinical trial results. View Abstract
Associations between worsening renal function and 30-day outcomes among Medicare beneficiaries hospitalized with heart failure. View Abstract
Use of guideline-recommended therapies for heart failure in the Medicare population. View Abstract
Association of insurance status with inpatient treatment for coronary artery disease: findings from the Get With the Guidelines program. View Abstract
Recent nationwide trends in discharge statin treatment of hospitalized patients with stroke. View Abstract
Racial and ethnic differences in the treatment of acute myocardial infarction: findings from the Get With the Guidelines-Coronary Artery Disease program. View Abstract
Relationship between early physician follow-up and 30-day readmission among Medicare beneficiaries hospitalized for heart failure. View Abstract
Long-term outcomes of medicare beneficiaries with worsening renal function during hospitalization for heart failure. View Abstract
Treatment and risk in heart failure: gaps in evidence or quality? View Abstract
Left ventricular assist device destination therapy versus extended criteria cardiac transplant. View Abstract
Regional differences in quality of care and outcomes for the treatment of acute coronary syndromes: an analysis from the get with the guidelines coronary artery disease program. View Abstract
Clinical trials of pharmacological therapies in acute heart failure syndromes: lessons learned and directions forward. View Abstract
Process of care performance measures and long-term outcomes in patients hospitalized with heart failure. View Abstract
Relationships between emerging measures of heart failure processes of care and clinical outcomes. View Abstract
Characteristics, performance measures, and in-hospital outcomes of the first one million stroke and transient ischemic attack admissions in get with the guidelines-stroke. View Abstract
Are quality improvements associated with the Get With the Guidelines-Coronary Artery Disease (GWTG-CAD) program sustained over time? A longitudinal comparison of GWTG-CAD hospitals versus non-GWTG-CAD hospitals. View Abstract
Efficacy and safety of nesiritide in patients with acute decompensated heart failure. View Abstract
Clinical effectiveness of implantable cardioverter-defibrillators among medicare beneficiaries with heart failure. View Abstract
A validated risk score for in-hospital mortality in patients with heart failure from the American Heart Association get with the guidelines program. View Abstract
Role of guanylate cyclase modulators in decompensated heart failure. View Abstract
Quality of care and in-hospital outcomes in patients with coronary heart disease in rural and urban hospitals (from Get With the Guidelines-Coronary Artery Disease Program). View Abstract
Impact of left ventricular assist device bridging on posttransplant outcomes. View Abstract
Trends in the use of evidence-based treatments for coronary artery disease among women and the elderly: findings from the get with the guidelines quality-improvement program. View Abstract
Use of aldosterone antagonists in heart failure. View Abstract
Characteristics and in-hospital outcomes for nonadherent patients with heart failure: findings from Get With The Guidelines-Heart Failure (GWTG-HF). View Abstract
Quality of care for atrial fibrillation among patients hospitalized for heart failure. View Abstract
The dissociation between door-to-balloon time improvement and improvements in other acute myocardial infarction care processes and patient outcomes. View Abstract
Predictors of cardiac rehabilitation referral in coronary artery disease patients: findings from the American Heart Association's Get With The Guidelines Program. View Abstract
Weekend hospital admission and discharge for heart failure: association with quality of care and clinical outcomes. View Abstract
Quality of care for acute coronary syndrome patients with known atherosclerotic disease: results from the Get With the Guidelines Program. View Abstract
Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. View Abstract
Variation in perioperative vasoactive therapy in cardiovascular surgical care: data from the Society of Thoracic Surgeons. View Abstract
End points for clinical trials in acute heart failure syndromes. View Abstract
Representativeness of a national heart failure quality-of-care registry: comparison of OPTIMIZE-HF and non-OPTIMIZE-HF Medicare patients. View Abstract
Phase III clinical trial end points in acute heart failure syndromes: a virtual roundtable with the Acute Heart Failure Syndromes International Working Group. View Abstract
Linking inpatient clinical registry data to Medicare claims data using indirect identifiers. View Abstract
BNP-guided heart failure therapy in older patients. View Abstract
Influence of age on the management of heart failure: findings from Get With the Guidelines-Heart Failure (GWTG-HF). View Abstract
Association between mortality and persistent use of beta blockers and angiotensin-converting enzyme inhibitors in patients with left ventricular systolic dysfunction and coronary artery disease. View Abstract
Advancing care for acute heart failure--no time to relax. View Abstract
Door-to-balloon times in hospitals within the get-with-the-guidelines registry after initiation of the door-to-balloon (D2B) Alliance. View Abstract
Hospital variation and characteristics of implantable cardioverter-defibrillator use in patients with heart failure: data from the GWTG-HF (Get With The Guidelines-Heart Failure) registry. View Abstract
A change of heart. View Abstract
Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry. View Abstract
Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF). View Abstract
Early and long-term outcomes of heart failure in elderly persons, 2001-2005. View Abstract
Sex differences in medical care and early death after acute myocardial infarction. View Abstract
Standardizing care for acute decompensated heart failure in a large megatrial: the approach for the Acute Studies of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure (ASCEND-HF). View Abstract
Long-term outcomes and costs of ventricular assist devices among Medicare beneficiaries. View Abstract
Case report: treatment of androgen deficiency in the aging male. View Abstract
Association of patient case-mix adjustment, hospital process performance rankings, and eligibility for financial incentives. View Abstract
Quality of care and outcomes among patients with heart failure and chronic kidney disease: A Get With the Guidelines -- Heart Failure Program study. View Abstract
Influence of hospital length of stay for heart failure on quality of care. View Abstract
Patient and implanting physician factors associated with mortality and complications after implantable cardioverter-defibrillator implantation, 2002-2005. View Abstract
Infectious complications in extended criteria heart transplantation. View Abstract
Cholesterol levels and in-hospital mortality in patients with acute decompensated heart failure. View Abstract
Use of cardiac resynchronization therapy in patients hospitalized with heart failure. View Abstract
Weekend/holiday versus weekday hospital discharge and guideline adherence (from the American Heart Association's Get with the Guidelines--Coronary Artery Disease database). View Abstract
Comparative effectiveness of angiotensin-converting-enzyme inhibitors: is an ACE always an ace? View Abstract
Impact of heart failure on patients undergoing major noncardiac surgery. View Abstract
Translating evidence into practice: use of statins in real-world patients with heart failure. View Abstract
Achieving rapid reperfusion with primary percutaneous coronary intervention remains a challenge: insights from American Heart Association's Get With the Guidelines program. View Abstract
Incidence and prevalence of heart failure in elderly persons, 1994-2003. View Abstract
Patterns and implications of B-type natriuretic peptide measurement in patients with non-ST-segment elevation acute coronary syndromes. View Abstract
Sex differences in the use of implantable cardioverter-defibrillators for primary and secondary prevention of sudden cardiac death. View Abstract
Sex and racial differences in the use of implantable cardioverter-defibrillators among patients hospitalized with heart failure. View Abstract
Medical therapies and invasive treatments for coronary artery disease by body mass: the "obesity paradox" in the Get With The Guidelines database. View Abstract
A decade of short-term outcomes in post cardiac surgery ventricular assist device implantation: data from the Society of Thoracic Surgeons' National Cardiac Database. View Abstract
Heart failure with preserved left ventricular systolic function among patients with non-ST-segment elevation acute coronary syndromes. View Abstract
Topical anesthesia with EMLA reduces pain during endomyocardial biopsy: a randomized trial. View Abstract
Contemporary performance of surgical ventricular restoration procedures: data from the Society of Thoracic Surgeons' National Cardiac Database. View Abstract
A centralised telephone intervention reduced combined all cause mortality or admission for worsening HF in chronic heart failure. View Abstract
Implantable left ventricular assist devices: new hope for patients with end-stage heart failure. View Abstract
Left ventricular assessment in myocardial infarction: the VALIANT registry. View Abstract
Recurrence of cardiac sarcoidosis in a heart transplant recipient. View Abstract
Outcomes with an alternate list strategy for heart transplantation. View Abstract
Review: implantable cardioverter defibrillators reduce all-cause mortality in nonischemic cardiomyopathy. View Abstract
Outcomes in heart failure patients after major noncardiac surgery. View Abstract
Preoperative evaluation for major noncardiac surgery: focusing on heart failure. View Abstract
Cardiac transplantation at Duke University Medical Center. View Abstract
Sparing a little may save a lot: lessons from the Studies of Left Ventricular Dysfunction (SOLVD). View Abstract
Highlights from the American College of Cardiology Annual Scientific Sessions 2003: March 28 to April 2, 2003. View Abstract
Highlights from the American Heart Association annual scientific sessions 2002: November 17 to 20, 2002. View Abstract